mupirocin profile

Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	446596
CHEMBL ID	719
CHEBI ID	7025
CHEBI ID	94519
SCHEMBL ID	1027618
SCHEMBL ID	3291
MeSH ID	M0025454

Synonym
smr000471888
MLS001074711
BIDD:GT0320
bactroban
brl-4910a
mupirocin, >=92% (hplc), powder
mupirocine [french]
(e)-(2s,3r,4r,5s)-5-((2s,3s,4s,5s)-2,3-epoxy-5-hydroxy-4-methylhexyl)tetrahydro-3,4-dihydroxy-beta-methyl-2h-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid
brl 4910a
plasimine
mupirocinum [latin]
8-carboxyoctyl (e)-4-(2s,3r,4r,5s)-5-((2s,3s,4s,5s)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2h-pyran-2-yl)-3-methylcrotonat
turixin
mupirocina [spanish]
nonanoic acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)methyl)-2h-pyran-2-yl)-2-butenyl)oxy)-, (2s-(2alpha(e),3beta,4beta,5alpha(2r,3r(1r,2r))))-
MRC ,
mupirocin
12650-69-0
pseudomonic acid a
pseudomonic acid
mupirocine
DB00410
9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3- [(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
1JZS
mupirocin (usp/inn)
bactroban (tn)
D01076
centany (tn)
NCGC00164554-03
trans-pseudomonic acid
chebi:7025 ,
nsc-759182
bactoderm
CHEMBL719 ,
9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3-[(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
9-(4-((2s,3r,4r,5s)-3,4-dihydroxy-5-(((2s,3s)-3-((2s,3s)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)-tetrahydro-2h-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic acid
9-((e)-4-((2s,3r,4r,5s)-3,4-dihydroxy-5-(((2s,3s)-3-((2s,3s)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)-tetrahydro-2h-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic acid
cid_446596
9-(4-{3,4-dihydroxy-5-[3-(2-hydroxy-1-methyl-propyl)-oxiranylmethyl]-tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)-nonanoic acid (mupirocin)
bdbm50290686
9-((e)-4-{(2s,3r,4r,5s)-3,4-dihydroxy-5-[(2s,3s)-3-((1s,2s)-2-hydroxy-1-methyl-propyl)-oxiranylmethyl]-tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)-nonanoic acid
centany
cpd000471888
HMS3259L05
bactroban ointment
unii-d0gx863oa5
mupirocin neo-sensitabs
d0gx863oa5 ,
nsc 759182
mupirocin [usan:usp:inn:ban]
dtxcid8026438
cas-12650-69-0
dtxsid0046438 ,
tox21_112183
nsc759182
pharmakon1600-01505706
mupirocinum
mupirocina
HMS2234E20
AKOS015994756
9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3-[(1s,2s)-2-hydroxy-1-methyl-propyl]oxiran-2-yl]methyl]tetrahydropyran-2-yl]-3-methyl-but-2-enoyl]oxynonanoic acid
mupirocin [inn]
9-[[(2e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3-[(1s,2s)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]tetrahydro-2h-pyran-2-yl]-3-methylbut-2-enoyl]oxy]nonanoic acid
mupirocin [usp monograph]
mupirocin [vandf]
mupirocin [mart.]
mupirocin [ep monograph]
l-talo-non-2-enonic acid, 5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2s,3s)-3-[(1s,2s)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]-3-methyl-, 8-carboxyoctyl ester, (2e)-
mupirocin [orange book]
mupirocin [usan]
(2e)-5,9-anhydro-2,3,4,8-tetradeoxy-8-(((2s,3s)-3-((1s,2s)-2-hydroxy-1-methylpropyl)oxiranyl)methyl)-3-methyl-l-talo-non-2-enonic acid, 8-carboxyoctyl ester
mupirocin [mi]
mupirocin [who-dd]
mupirocin [usp impurity]
nonanoic acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)methyl)-2h-pyran-2-yl)-2-butenyl)oxy)-, (2s-(2.alpha.(e),3.beta.,4.beta.,5.alpha.(2r,3r(1r,2r))))-
mupirocin [green book]
(e)-(2s,3r,4r,5s)-5-[(2s,3s,4s,5s)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-beta-methyl-2h-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid
mupirocin [usp-rs]
SCHEMBL1027618
CCG-213522
MINDHVHHQZYEEK-HBBNESRFSA-N
NC00620
SCHEMBL3291
KS-5137
mupirocin, pseudomonic acid a
mupirocin, antibiotic for culture media use only
M-8680
9-({(2e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-({(2s,3s)-3-[(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)tetrahydro-2h-pyran-2-yl]-3-methylbut-2-enoyl}oxy)nonanoic acid
FD12069
HY-B0958
AB01563109_01
mfcd01711620
9-{[(2e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-{[(2s,3s)-3-[(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl}oxan-2-yl]-3-methylbut-2-enoyl]oxy}nonanoic acid
80558-54-9
mupirocin, united states pharmacopeia (usp) reference standard
CHEBI:94519
sr-05000001947
SR-05000001947-2
SR-05000001947-1
mupirocin; 9-[[(2e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3-[(1s,2s)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]tetrahydro-2h-pyran-2-yl]-3-methylbut-2-enoyl]oxy]nonanoic acid
SBI-0206892.P001
NCGC00164554-05
HMS3712K03
9-(((e)-4-((2s,3r,4r,5s)-3,4-dihydroxy-5-(((2s,3s)-3-((2s,3s)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2h-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoic acid
9-((e)-4-((2s,3r,4r,5s)-3,4-dihydroxy-5-(((2s,3s)-3-((2s,3s)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2h-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic acid
S4297
mupirocin,(s)
AS-11580
M2955
Q413578
BRD-K15262564-001-06-9
NCGC00164554-06
gtpl10916
nsc815348
nsc-815348
rel-9-(((e)-4-((2s,3r,4r,5s)-3,4-dihydroxy-5-(((2s,3s)-3-((2s,3s)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2h-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoic acid
EN300-21680763

Excerpt	Reference	Relevance
"Mupirocin is a clinically important antibiotic produced by Pseudomonas fluorescens NCIMB 10586 that is assembled by a complex trans-AT polyketide synthase. "	( Programmed Iteration Controls the Assembly of the Nonanoic Acid Side Chain of the Antibiotic Mupirocin. Akter, N; Crump, MP; Mbatha, SZ; Race, PR; Rowe, MT; Song, Z; Walker, PD; Weir, ANM; Williams, C; Willis, CL; Winter, AJ, 2022)	2.38
"Mupirocin is a promising broad-spectrum antibiotic that is effective in treating MRSA infections. "	( Development, characterization and pharmacokinetics of mupirocin-loaded nanostructured lipid carriers (NLCs) for intravascular administration. Alcantara, KP; Castillo, AL; Zulfakar, MH, 2019)	2.21
"Mupirocin is an antibiotic with a unique mode of action that is active against MRSA, but its clinical use is restricted to topical administration because of its limited plasma stability and rapid degradation to inactive metabolites."	( Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus infections. Barenholz, Y; Cern, A; Goldmann, O; Medina, E; Müsken, M; Rohde, M; Weiss, W, 2019)	1.64
"Mupirocin is an antibacterial drug. "	( Development of Emulgel Delivery of Mupirocin for Treatment of Skin Infection. Jagdale, SC; Kothekar, PV, 2020)	2.28
"Mupirocin is a topical antimicrobial agent which is very effective against S.aureus infection."	( Formulation development of cream with mupirocin and essential oils for eradication of biofilm mediated antimicrobial resistance. Baberoselin, R; Geetha, N; Karuppaiah, A; Nithyanth, M; Ramesh, S; Sundaramoorthy, M; Veintramuthu, S, 2021)	1.61
"Mupirocin ointment is a widely used topical drug for the treatment of bacterial skin infections. "	( Anti-biofilm properties of a mupirocin spray formulation against Escherichia coli wound infections. Bakkiyaraj, D; Nakpheng, T; Padmavathi, AR; Srichana, T; Sritharadol, R, 2017)	2.19
"Mupirocin is a topical antibacterial drug used for the treatment of staphylococcal infections, including meticillin-resistant Staphylococcus pseudintermedius (MRSP). "	( Low prevalence of mupirocin resistance in Staphylococcus pseudintermedius isolates from canine pyoderma in Korea. Hwang, CY; Hyun, JE; Kang, JH; Park, JH, 2018)	2.26
"Mupirocin is a useful topical antibacterial for MRSP, but a clinical MRSP isolate that had not previously been exposed to mupirocin exhibited the high-level mupirocin resistance in phenotype and genotype. "	( Low prevalence of mupirocin resistance in Staphylococcus pseudintermedius isolates from canine pyoderma in Korea. Hwang, CY; Hyun, JE; Kang, JH; Park, JH, 2018)	2.26
"Mupirocin is a useful antibiotic against superficial skin infections. "	( Mupirocin at Subinhibitory Concentrations Induces Biofilm Formation in Staphylococcus aureus. Hamada, M; Ishii, Y; Kimura, S; Srichana, T; Sritharadol, R; Tateda, K, 2018)	3.37
"Mupirocin is an antibiotic from monocarboxylic acid class used as antibacterial agent against methicillin-resistant Staphylococcus aureus (MRSA) and can be obtained as a mixture of four pseudomonic acids by Pseudomonas fluorescens biosynthesis. "	( Mupirocin: applications and production. Blaga, AC; Cascaval, D; Galaction, AI; Tucaliuc, A, 2019)	3.4
"Mupirocin is a topical antibiotic used for decolonization of meticillin-susceptible S. aureus (MSSA) and meticillin-resistant S. aureus (MRSA), both in patients and in healthcare personnel, and for treatment of local skin and soft tissue infections caused by S. aureus and streptococcal species. "	( Clinical relevance of mupirocin resistance in Staphylococcus aureus. Bonten, MJ; Hetem, DJ, 2013)	2.15
"Mupirocin is a topical antimicrobial agent and part of most Staphylococcus aureus decolonization regimens. "	( Mupirocin susceptibility in Staphylococcus aureus nasal and oropharyngeal isolates from Brazilian children. Berezin, EN; Carvalho, RL; Mimica, MJ; Pereira, MF; Scheffer, DK, 2014)	3.29
"Mupirocin is an antibiotic that is currently restricted to topical administration because of rapid hydrolysis in vivo to its inactive metabolite."	( Effect of solubilizing agents on mupirocin loading into and release from PEGylated nanoliposomes. Barenholz, Y; Cern, A; Goldblum, A; Nativ-Roth, E, 2014)	1.41
"Mupirocin is a commercially available antibiotic that acts on bacterial isoleucyl-tRNA synthetase, thereby inhibiting protein synthesis and preventing bacterial infection. "	( Enzymatic glycosylation of the topical antibiotic mupirocin. Ghimire, GP; Pandey, RP; Parajuli, P; Pokhrel, AR; Sohng, JK, 2014)	2.1
"Mupirocin is a polyketide antibiotic with broad antibacterial activity. "	( Antimicrobial properties of Pseudomonas strains producing the antibiotic mupirocin. Cornelis, P; Cornu, B; Matthijs, S; Ongena, M; Thomas, CM; Vander Wauven, C; Ye, L, 2014)	2.08
"Mupirocin is a topical antibiotic largely used to eradicate staphylococcal nasal carriage. "	( Mupirocin Resistance in Isolates of Staphylococcus spp. from Nasal Swabs in a Tertiary Hospital in France. Dumitrescu, O; Dupieux, C; Flammier, S; Laurent, F; Rasigade, JP; Sapin, A; Tristan, A; Trouillet-Assant, S; Vandenesch, F, 2015)	3.3
"Mupirocin is a topical antimicrobial used to decolonize patients who carry methicillin-resistant Staphylococcus aureus (MRSA), and the topical agent retapamulin may be a potential alternative therapy. "	( In Vitro Activity of Retapamulin and Antimicrobial Susceptibility Patterns in a Longitudinal Collection of Methicillin-Resistant Staphylococcus aureus Isolates from a Veterans Affairs Medical Center. Black, JA; Clarridge, JE; Harrington, AT, 2015)	1.86
"Mupirocin ointment is an effective treatment for nasal carriers."	( Pre-cesarean Staphylococcus aureus nasal screening and decolonization: a prospective randomized controlled trial. Egozi, T; Hallak, M; Naeh, A; Shrem, G; Walfisch, A, 2016)	1.16
"Mupirocin is a topical antibiotic for methicillin-resistant Staphylococcus aureus (MRSA) decolonization in hospital settings and nursing homes and is used as a highly effective antibiotic against MRSA. "	( Distribution of high-level mupirocin resistance among clinical MRSA. Amin, M; Hedayati Ch, M; Imani Fooladi, AA; Kiyani, N; Mahmoodzadeh Hosseini, H, 2017)	2.19
"Mupirocin is a mixture of pseudomonic acids (PAs)."	( Selected Mutations Reveal New Intermediates in the Biosynthesis of Mupirocin and the Thiomarinol Antibiotics. Connolly, J; Cox, RJ; Crump, MP; Gao, SS; Hothersall, J; Race, PR; Simpson, TJ; Song, Z; Stevens, ER; Thomas, CM; Wang, L; Willis, CL; Winn, PJ, 2017)	1.41
"Mupirocin is an antibiotic used for eradication and infection control of methicillin-resistant Staphylococcus aureus (MRSA). "	( Mupirocin resistance screening of methicillin-resistant Staphylococcus aureus isolates at Madigan Army Medical Center. Braun, L; Fairchok, M; Hogue, JS; Perkins, D; Viscount, HB, 2008)	3.23
"Mupirocin is a topical antimicrobial agent which is used for the treatment of skin and postoperative wound infections, and the prevention of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA). "	( Phenotypic and molecular characterization of Staphylococcus aureus isolates expressing low- and high-level mupirocin resistance in Nigeria and South Africa. Lin, J; Shittu, AO; Udo, EE, 2009)	2.01
"Mupirocin is a topical antimicrobial agent that is used for the treatment of skin and postoperative wound infections, and the prevention of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA). "	( Constitutive expression of the ileS-2 gene responsible for high-level mupirocin resistance in Staphylococcus aureus. Bastos, MDCF; Cavalcanti, EDC; Giambiagi-deMarval, M; Laport, MS; Oliveira, NEM, 2009)	2.03
"Mupirocin (Mup) is an isoleucyl-adenylate analog that inhibits the essential enzyme, isoleucyl-tRNA synthetase (IleRS)."	( Amplification of the gene for isoleucyl-tRNA synthetase facilitates adaptation to the fitness cost of mupirocin resistance in Salmonella enterica. Andersson, DI; Maisnier-Patin, S; Paulander, W, 2010)	1.3
"Mupirocin is a topical antimicrobial used to treat bacterial skin infections."	( In vitro susceptibility testing of meticillin-resistant and meticillin-susceptible staphylococci to mupirocin and novobiocin. Dick, HL; Fulham, KS; Hosgood, G; Lemarie, SL, 2011)	1.31
"Mupirocin is a topical antimicrobial used to eradicate methicillin-resistant Staphylococcus aureus (MRSA) colonization, usually in the absence of susceptibility testing. "	( Association of high-level mupirocin resistance and multidrug-resistant methicillin-resistant Staphylococcus aureus at an academic center in the midwestern United States. Boyle-Vavra, S; Cadilla, A; Daum, RS; David, MZ, 2011)	2.11
"Mupirocin is a polyketide antibiotic produced by Pseudomonas fluorescens. "	( Mupirocin: biosynthesis, special features and applications of an antibiotic from a gram-negative bacterium. Gurney, R; Thomas, CM, 2011)	3.25
"Mupirocin is an antibiotic commonly used in selective media for the isolation of bifidobacteria. "	( Insights into physiological and genetic mupirocin susceptibility in bifidobacteria. Baruffini, E; Bottacini, F; Foroni, E; Lodi, T; Serafini, F; Turroni, F; van Sinderen, D; Ventura, M; Viappiani, A, 2011)	2.08
"Mupirocin is a topical antibiotic used for the treatment of skin infections and the eradication of methicillin-resistant Staphylococcus aureus carriage. "	( MupB, a new high-level mupirocin resistance mechanism in Staphylococcus aureus. Alexander, DC; Longtin, J; Louie, L; Low, DE; Melano, RG; Seah, C; Simor, A, 2012)	2.13
"The mupirocin cluster is a combination of six larger ORFs (mmpA-F), containing several domains resembling the multifunctional proteins of polyketide synthase and fatty acid synthase type I systems, and individual genes (mupA-X and macpA-E), some of which show similarity to type II systems (mupB, mupD, mupG, and mupS)."	( Characterization of the mupirocin biosynthesis gene cluster from Pseudomonas fluorescens NCIMB 10586. Cooper, SM; El-Sayed, AK; Hothersall, J; Simpson, TJ; Stephens, E; Thomas, CM, 2003)	1.11
"Mupirocin is a topical drug used to remove S."	( Oxacillin- and mupirocin-resistant Staphylococcus aureus: in vitro activity of silver sulphadiazine and cerium nitrate in hospital strains. Dadalti, P; Fonseca, LS; Santos, KR; Schuenck, RP; Silva, MG, 2004)	1.4
"Mupirocin is an antimicrobial agent commonly used to treat staphylococcal infection or to eliminate persistent carriage. "	( Interpretive criteria for mupirocin susceptibility testing of Staphylococcus spp. using CLSI guidelines. Creagh, S; Lucey, B, 2007)	2.08
"Mupirocin is a "gold standard" for activity against MRSA."	( Thematic review series: skin lipids. Antimicrobial lipids at the skin surface. Brogden, KA; Dawson, DV; Drake, DR; Wertz, PW, 2008)	1.07
"Mupirocin is a natural antibiotic from Pseudomonas fluorescens which is available as a 2% ointment. "	( Intranasal mupirocin prophylaxis in elective surgery. A review of published studies. Hemmer, W; Luz, K; Panknin, HT; Stecher, J; Trautmann, M, 2008)	2.18
"Mupirocin is a novel topical antibiotic with excellent antibacterial activity against staphylococci."	( The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. Perl, TM; Wenzel, RP, 1995)	1.01
"Mupirocin is a topically applied drug that is very active in the eradication of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA). "	( Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Blázquez, MJ; Bouza, E; Cercenado, E; Guerrero, MC; Menarguez, MC; Moreno, S; Parras, F, 1995)	2.05
"Mupirocin is a novel topical antibiotic with excellent antibacterial activity against staphylococci, including MRSA."	( The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. Hudson, IR, 1994)	1.31
"Mupirocin nasal is a successful therapy for removing nasal carriage of S."	( Treatment of familial staphylococcal infection--comparison of mupirocin nasal ointment and chlorhexidine/neomycin (Naseptin) cream in eradication of nasal carriage. Joy, G; Leigh, DA, 1993)	1.25
"Mupirocin is a naturally occurring antibiotic produced by submerged fermentation of Pseudomonas fluorescens."	( Intranasal mupirocin for outbreaks of methicillin-resistant Staphylococcus aureus. Bertino, JS, 1997)	1.41
"Mupirocin is a topical antibiotic with high in vitro anti-staphylococcal activity."	( Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. Barbosa, D; Canziani, ME; Draibe, S; Leme, IL; Manfredi, S; Pignatari, AC; Sader, H; Sesso, R, 1998)	1.24
"Mupirocin calcium cream is a newly reformulated topical antibiotic with a bactericidal spectrum specific for the pathogens that frequently cause secondary infections in superficial wounds. "	( Opportunities for mupirocin calcium cream in the emergency department. Williford, PM, )	1.91
"Mupirocin is a topical antimicrobial agent that has been successfully used to eradicate methicillin-resistant Staphylococcus aureus from the anterior nares and other sites of patients and health care personnel. "	( Emergence of mupirocin resistance in multiresistant Staphylococcus aureus clinical isolates belonging to Brazilian epidemic clone III::B:A. Figueiredo, AMS; Marangoni, D; Ormonde, LR; Ramos, RLB; Santos, MS; Siqueira, PLA; Teixeira, LA, 1999)	2.12
"Mupirocin is a unique antibiotic that is produced by Pseudomonas fluorescens, and is available for elimination of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA). "	( [Mupirocin resistant MRSA in Japan]. Kikuchi, K, 2001)	2.66
"Mupirocin is a potent topical anti-staphylococcal compound, but its effectiveness has been compromised by emerging resistance."	( Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Deshpande, LM; Fix, AM; Jones, RN; Pfaller, MA, 2002)	1.37
"Mupirocin is a novel antibiotic, for topical use only, which is unrelated in chemical structure and mode of action to any known class of antibacterial agent. "	( Overview of the role of mupirocin. Lamb, YJ, 1991)	2.03
"Mupirocin is a novel antibiotic totally unrelated in chemical structure and mode of action to any other clinically useful class of antibiotics. "	( The clinical development of mupirocin. Pappa, KA, 1990)	2.02
"Mupirocin appears to be a well-tolerated, albeit expensive, alternative to erythromycin for the treatment of impetigo."	( Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocin. Barton, LL; Friedman, AD; Schneller, DJ; Sharkey, AM; Swierkosz, EM, 1989)	1.23
"Mupirocin is a new, topical antibiotic effective for the treatment of impetigo. "	( Mupirocin: a new topical therapy for impetigo. Putnam, CD; Reynolds, MS, )	3.02
"Mupirocin is an investigational topical antibiotic used for treatment and prophylaxis of bacterial skin infections. "	( Topical mupirocin in the treatment of bacterial skin infections. Aronson, IK; Rumsfield, J; West, DP, 1986)	2.15

Excerpt	Reference	Relevance
"Mupirocin has a low risk of systemic and topical complications."	( Opportunities for mupirocin calcium cream in the emergency department. Williford, PM, )	1.19
"Mupirocin has been increasingly used for treatment of methicillin-susceptible S."	( Mupirocin resistance in Staphylococcus aureus: A systematic review and meta-analysis. Dadashi, M; Darban-Sarokhalil, D; Goudarzi, M; Hajikhani, B; van Belkum, A, 2020)	2.72
"Mupirocin has been used topically for treating skin and skin structure infections and for nasal decolonization before surgical interventions. "	( Susceptibility of Staphylococcus aureus to topical agents in the United States: a sentinel study. Biedenbach, DJ; Bouchillon, SK; Hackel, M; Hoban, DJ; Johnson, SA, 2014)	1.85
"Mupirocin has well-recognized antistaphylococcal activity, and its nasal formulation is approved for the eradication of SA nasal colonization."	( Efficacy of nasal Staphylococcus aureus eradication by topical nasal mupirocin in patients with perennial allergic rhinitis. Cohen, A; Kalinin, M; Kidon, M; Magen, E; Schlesinger, M; Weiler, Z; Zeldin, Y, 2008)	1.3
"Mupirocin has been extensively studied and shown to be effective."	( A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections. Chan, WH; Cheuk, A; Cheung, CC; Choy, WY; Chu, KH; Fung, KS; Lee, W; Tang, HL; Tong, KL; Yim, KF, )	1.08
"Mupirocin application has been introduced to combat S."	( Prevention of staphylococcal peritonitis in CAPD patients combining ablution and mupirocin. Abdul Rahman, IS; Al-Hwiesh, AK, 2008)	1.29
"Mupirocin nasal washes have been proposed as an efficacious treatment in such patients."	( Microbiological outcomes following mupirocin nasal washes for symptomatic, Staphylococcus aureus-positive chronic rhinosinusitis following endoscopic sinus surgery. Jervis-Bardy, J; Wormald, PJ, )	1.13
"Mupirocin has been used against Gram-positive pathogenic bacteria, and is a specific inhibitor of bacterial isoleucyl-tRNA synthetase. "	( Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. Choi, EC; Choi, S; Kim, S; Kim, SY; Lee, SW; Lee, YS; Yoon, GM; Yun, HJ, 2003)	2.02
"Mupirocin has been used in nursing homes to prevent the spread of methicillin-resistant Staphylococcus aureus (MRSA), despite the lack of controlled trials. "	( Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Bradley, SF; Galecki, AT; Kauffman, CA; McNeil, SA; Mody, L, 2003)	3.2
"Mupirocin has well-recognized antistaphylococcal activity, and its nasal formulation is approved by the Food and Drug Administration for the eradication of nasal colonization with MRSA."	( Treatment of chronic rhinosinusitis exacerbations due to methicillin-resistant Staphylococcus aureus with mupirocin irrigations. Batra, PS; Citardi, MJ; Hall, GS; Solares, CA, )	1.07
"Mupirocin E-test strips have been evaluated for their ease of use and accuracy in determining the susceptibilities of 171 strains of Staphylococcus spp., Streptococcus spp., Haemophilus influenzae, and Moraxella catarrhalis. "	( Evaluation of mupirocin E-test for determination of isolate susceptibility: comparison with standard agar dilution techniques. Durodie, J; Gisby, J; Hemingway, CP; Macpherson, I; Simpson, IN, 1995)	2.09
"Mupirocin ointment has been shown to be effective in eradicating Staphylococcus aureus nasal carriage in residents of a long-term care facility. "	( Mupirocin ointment with and without chlorhexidine baths in the eradication of Staphylococcus aureus nasal carriage in nursing home residents. Axelson, C; Bota, B; Stahl, C; Watanakunakorn, C, 1995)	3.18
"Mupirocin has become the topical agent of choice for the elimination of methicillin-resistant Staphylococcus aureus (MRSA) carriage. "	( Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). Eltringham, I, 1997)	3.18
"Mupirocin has a low risk of systemic and topical complications."	( Opportunities for mupirocin calcium cream in the emergency department. Williford, PM, )	1.19
"Mupirocin has been widely used for the clearance of nasal methicillin-resistant Staphylococcus aureus (MRSA) carriage during outbreaks, but no placebo-controlled trial has evaluated its value for eradicating MRSA carriage at multiple body sites in settings where MRSA is not epidemic. "	( Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Auckenthaler, R; Dharan, S; Harbarth, S; Herrault, P; Liassine, N; Pittet, D, 1999)	1.97
"Mupirocin (Mup) has been used extensively to prevent Staphylococcus aureus (SAu) infections in patients undergoing peritoneal dialysis (PD). "	( Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Falcón, TG; Pérez-Fontán, M; Rodríguez-Carmona, A; Rosales, M; Valdés, F, 2002)	3.2
"Mupirocin ointment has been used intranasally to eradicate S."	( The efficacy of mupirocin ointment and chlorhexidine body scrubs in the eradication of nasal carriage of Staphylococcus aureus among patients undergoing long-term hemodialysis. Bota, B; Brandt, J; Durkin, P; Santore, S; Stahl, CJ; Watanakunakorn, C, 1992)	1.35
"Mupirocin has excellent in vitro activity against staphylococci and most streptococci but less activity against other gram-positive and gram-negative bacteria."	( Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Hatfield, SM; Leyden, JJ; Parenti, MA, 1987)	2.44

Excerpt	Reference	Relevance
"Mupirocin showed lower inhibitory effects than bidwillon B on thymidine, uridine and glucose incorporation, but incorporation of isoleucine was completely blocked with this antibiotic."	( Synergistic effects of mupirocin and an isoflavanone isolated from Erythrina variegata on growth and recovery of methicillin-resistant Staphylococcus aureus. Etoh, H; Kato, K; Sato, M; Tanaka, H; Yamaguchi, R, 2004)	1.36

Excerpt	Reference	Relevance
"Mupirocin treatment effectively eliminated S."	( Nasal microbiome disruption and recovery after mupirocin treatment in Staphylococcus aureus carriers and noncarriers. Baede, VO; Barray, A; Lina, G; Rasigade, JP; Tavakol, M; Vos, MC, 2022)	1.7
"Mupirocin exposure was treated as time varying."	( Bacterial Infections in Neonates Following Mupirocin-Based MRSA Decolonization: A Multicenter Cohort Study. Bryant, K; Elward, A; Lessler, J; Milstone, AM; Pierce, R, 2017)	1.44
"Mupirocin treatment successfully converted all of the MRSA-positive macaques into non-carriers, suggesting the feasibility of this simple, one-step screening procedure for rapidly identifying MRSA carriers in large cohorts."	( A Simple Way to Eradicate Methicillin-Resistant Cho, K; Choi, EW; Kim, SJ; Kim, TM; Lee, KW; Lee, YS; Moon, SH; Park, H; Park, JB; Park, WJ, 2017)	1.18
"Mupirocin treatment resulted in a reduction in burden of log 10 (log R) of 2.59 cfu/nares compared with vehicle ( P < 0.0001). "	( A single dose of epidermicin NI01 is sufficient to eradicate MRSA from the nares of cotton rats. Derrick, JP; Halliwell, S; Sattar, A; Upton, M; Warn, P, 2017)	1.9
"Mupirocin-treated ears showed no significant difference in ABR thresholds compared to saline-treated ears."	( Auditory function after application of ototopical vancomycin and mupirocin solutions in a murine model. Kavanagh, K; Parham, K; Rutherford, KD, 2011)	1.33
"Mupirocin treatment had no significant effect on the incidence of exit-site infection and peritonitis attributable to other organisms."	( Prophylaxis against gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site. Chan, HW; Cheuk, A; Chu, KH; Fung, SK; Tong, MK; Tsang, WK; Wong, SS, 2003)	1.24
"One mupirocin treatment failure was due to exogenous MRSA recolonization."	( Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Auckenthaler, R; Dharan, S; Harbarth, S; Herrault, P; Liassine, N; Pittet, D, 1999)	1.01
"In mupirocin-treated patients, most (16/19) instances of nasal recolonization were with pretreatment strains (determined by means of by pulsed field gel electrophoresis); mupirocin resistance was not observed."	( A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. Chambers, HF; Gerberding, JL; Kartalija, M; Lee, BL; Martin, JN; Pasi, OG; Perdreau-Remington, F; Täuber, MG; Webb, M, 1999)	1.1
"Mupirocin treatment produced similar clinical results to oral erythromycin and was superior in the eradication of S aureus, including antibiotic-resistant S aureus."	( Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Eaglstein, WH; Marshall, DA; Mertz, PM; Montalvo, J; Piovanetti, Y, 1989)	1.43
"The mupirocin-treated group had a significantly higher benefit:risk ratio than the erythromycin-treated group as measured by the investigator's global evaluation (P = 0.01)."	( Topical mupirocin vs. systemic erythromycin treatment for pyoderma. McLinn, S, 1988)	1.19
"Treatment with mupirocin spray resulted in significant antibacterial and anti-biofilm activities (inhibition and disruption) with single spray and sub-actual dose concentrations at par with the commercial ointment concentration."	( Anti-biofilm properties of a mupirocin spray formulation against Escherichia coli wound infections. Bakkiyaraj, D; Nakpheng, T; Padmavathi, AR; Srichana, T; Sritharadol, R, 2017)	1.09
"Treatment of mupirocin reduced the risks of ESI and peritonitis due to all organisms by 57% (95% CI: 0.46-0.66) and 41% (95% CI: 0.24-0.54), respectively."	( Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Tu, W; Xu, C; Xu, G, 2010)	2.16
"Treatment with mupirocin nasal washes in S. "	( Microbiological outcomes following mupirocin nasal washes for symptomatic, Staphylococcus aureus-positive chronic rhinosinusitis following endoscopic sinus surgery. Jervis-Bardy, J; Wormald, PJ, )	0.76
"Treatment with mupirocin can eradicate the organism in the short term, and prophylactic treatment of colonized patients may prevent postoperative S."	( Impact of treating Staphylococcus aureus nasal carriers on wound infections in cardiac surgery. Errett, L; Fong, IW; Konvalinka, A, 2006)	0.67
"Treatment with mupirocin ointment can reduce the rate of nasal carriage and may prevent postoperative S."	( Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. Cullen, JJ; French, PP; Herwaldt, LA; Perl, TM; Pfaller, MA; Sheppard, D; Twombley, J; Wenzel, RP; Zimmerman, MB, 2002)	1.04
"Re-treatment with mupirocin was successful in 66% of the cases, compared to 20% for neomycin."	( Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. Cao, M; Fernández-Rivera, C; Moncalián, J; Pérez-Fontán, M; Rodríguez-Carmona, A; Rosales, M; Valdés, F, 1992)	0.85

Excerpt	Reference	Relevance
" Mupirocin 2% ointment proved to be effective and safe in the treatment of primary and secondary skin infections."	( Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections--an open multicentre trial. Bork, K; Brauers, J; Kresken, M, 1989)	1.49
"05%) was uniformly toxic to both cultured human cells and microorganisms; (2) nitrofurazone (0."	( Cytotoxicity testing of topical antimicrobial agents on human keratinocytes and fibroblasts for cultured skin grafts. Boyce, ST; Holder, IA; Warden, GD, )	0.13
"05%) was found to be safe and very effective by physicians in the treatment of infected dermatoses in 94."	( Evaluation of safety and efficacy of supirocin-B (mupirocin 2% + betamethasone dipropionate 0.05%) in infected dermatoses--a post marketing study. Desai, A; Janaki, VR; Mittal, RR; Savant, S; Sengupta, S, 2000)	0.56
" Mupirocin cream was as well tolerated as cephalexin; 9% and 13% of patients reported adverse events related or possibly related to study medication in the mupirocin and cephalexin groups, respectively."	( A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. Bushnell, WD; Capin, LR; Cupo, MA; Parish, LC; Rist, T; Sulica, V, 2002)	1.49
"0% ointment is an effective and safe therapeutic regimen in atopic dermatitis."	( Efficacy and safety of combination ointment "fluticasone propionate 0.005% plus mupirocin 2.0%" for the treatment of atopic dermatitis with clinical suspicion of secondary bacterial infection: an open label uncontrolled study. Khobragade, KJ, )	0.36
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" No patients in the intervention group had adverse drug events from mupirocin and chlorhexidine use."	( Safety and Efficacy of Universal Postoperative Decolonization for Kidney Transplant Recipients. Bias, TE; Boyle, SM; Doyle, A; Harhay, MN; Lee, DH; Malat, G; Ranganna, K; Talluri, S, 2020)	0.79
" The most common treatment-emergent adverse events (TEAEs) were rhinorrhoea and nasal dryness (15."	( A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonisation of Staphylococcus aureus: A previously investigated 0.5mg/g viscosified gel formulation versus a modified formulation Fulton, SA; Gray, WA; Griffiss, JM; Jacobs, MR; O'Riordan, MA; Proskin, HM; Salata, RA; Winkle, P; Yendewa, GA, 2020)	0.56
"Oxymetazoline nasal spray, mupirocin ointment, and clotrimazole cream are safe and effective as off-label medications for tympanostomy tube care in children."	( Oxymetazoline, Mupirocin, Clotrimazole-Safe, Effective, Off-Label Agents for Tympanostomy Tube Care. Isaacson, G, 2020)	1.21
" The MLH formulation was safe and effective in burn wound healing."	( Safety and Biocompatibility of Mupirocin Nanoparticle-Loaded Hydrogel on Burn Wound in Rat Model. Chunhachaichana, C; Kaewpaiboon, S; Kamlungmak, S; Mudhar Bintang, MAK; Nakpheng, T; Prom-In, S; Srichana, T; Suwandecha, T, 2021)	0.91

Excerpt	Reference	Relevance
" The MNLC 1 also showed a significant increase in plasma concentration in rabbits following IV administration thus, demonstrating an enhancement on its pharmacokinetic profile as compared to free mupirocin."	( Development, characterization and pharmacokinetics of mupirocin-loaded nanostructured lipid carriers (NLCs) for intravascular administration. Alcantara, KP; Castillo, AL; Zulfakar, MH, 2019)	0.95

Excerpt	Reference	Relevance
" The study confirms that MRSA can be eradicated by means of washing with an antiseptic combined with mupirocin treatment."	( Eradication of MRSA from carriers by means of whole-body washing with an antiseptic in combination with mupirocin nasal ointment. Höffler, U; Siebert, J; Sloot, N, 1999)	0.73
" Decolonization was performed by intranasal application of mupirocin, combined with an octenidine dihydrochloride bodywash over a period of five days."	( Methicillin-resistant Staphylococcus aureus whole-body decolonization among hospitalized patients with variable site colonization by using mupirocin in combination with octenidine dihydrochloride. Gatermann, S; Mueller, C; Muhr, G; Rohr, U; Wilhelm, M, 2003)	0.76
" To explore strategies to overcome resistance development, we studied the effects of rifalazil in combination with several different antibiotics in an in vitro time-kill model, against both log phase and stationary phase Staphylococcus aureus cells."	( Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro. Murphy, CK; Osburne, MS; Rothstein, DM, 2006)	0.56
"The purpose of this study was to evaluate the potential irritating effects and the systemic exposure level of an antibacterial ointment containing REP8839 as a single agent or in combination with mupirocin versus Bactroban Nasal in rabbits."	( An intranasal irritation assessment of antibacterial ointment alone or in combination with mupirocin versus Bactroban Nasal in rabbits. Bell, SJ; Colagiovanni, DB; Faqi, AS; Gill, S, 2009)	0.76
"The antimicrobial activities of tetracycline, mupirocin, and fusidic acid are tested in combination with Epicatechin Gallate (ECG), and Ethyl Gallate (EG) using 2 Methicillin resistant (MRSA) and 2 Methicillin sensitive (MSSA) strains of Staphylococcus aureus."	( In vitro drug interactions of gallates with antibiotics in Staphylococcus Aureus. Chu Sing Lim, L; Sakharkar, KR; Sakharkar, MK; Soe, WM; Tzer Pin Lin, R, 2010)	0.62
"This study was conducted to compare the efficacy of hydrocortisone cream, combined with mupirocin or alone with emmolient ointment for the treatment of mild to moderate AD in infants between six months and two years of age."	( Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age - a randomized double blind pilot trial. Canpolat, F; Erkoçoğlu, M; Kandi, B; Kocabaş, CN; Tezer, H, 2012)	0.86
" Also there was a significant improvement in patients combined with mupirocin ointment [74% (20 of 27)]."	( Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age - a randomized double blind pilot trial. Canpolat, F; Erkoçoğlu, M; Kandi, B; Kocabaş, CN; Tezer, H, 2012)	0.87
"Monotherapy with hydrocortisone ointment is the main treatment in infants with mild to moderate AD and combination with mupirocin is safe and effective often needed because of possible Staphylococcus carriage."	( Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age - a randomized double blind pilot trial. Canpolat, F; Erkoçoğlu, M; Kandi, B; Kocabaş, CN; Tezer, H, 2012)	0.85

Excerpt	Reference	Relevance
"To determine the bioavailability of mupirocin in human nasal secretions and to assess whether the contents of nasal secretions interact appreciably with this antibiotic."	( The bioavailability of mupirocin in nasal secretions in vitro. Hill, RL, 2002)	0.9
"The comparative bioavailability of mupirocin and chlorhexidine in nasal secretions was determined by bioassay after one, four, and eight hours of incubation with pooled secretions from three subjects."	( The bioavailability of mupirocin in nasal secretions in vitro. Hill, RL, 2002)	0.9
"The high bioavailability of mupirocin in nasal secretions results from the lack of appreciable molecular interactions."	( The bioavailability of mupirocin in nasal secretions in vitro. Hill, RL, 2002)	0.92
" This is followed by a discussion on more recent developments in the field and the bioavailability problem."	( Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. Van Aerschot, A; Vondenhoff, GH, 2011)	0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" Patients were assigned at random to receive 4 to 10 days' treatment with either mupirocin applied 3-times daily or one of the oral antibiotics in the dosage normally used by the general practitioner for skin infections."	( A comparison of the new topical antibiotic mupirocin ('Bactroban') with oral antibiotics in the treatment of skin infections in general practice. Ah Chan, M; Fetherston, J; Hague, IK; Haycock, D; Hunter, P; Kanji, K; Robertson, WD; Villiger, JW, 1986)	0.76
"The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of mupirocin are reviewed."	( Intranasal mupirocin for outbreaks of methicillin-resistant Staphylococcus aureus. Bertino, JS, 1997)	0.9
" aureus nasal carriage in HIV-infected patients for several weeks; however, since the effect waned over time, intermittent dosing regimens should be considered for long-term eradication."	( A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. Chambers, HF; Gerberding, JL; Kartalija, M; Lee, BL; Martin, JN; Pasi, OG; Perdreau-Remington, F; Täuber, MG; Webb, M, 1999)	0.59
"The effect of topically applied retapamulin ointment was evaluated using various dosing regimens in the Staphylococcus aureus and Streptococcus pyogenes wound infection model."	( Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic. Hoover, J; Page, R; Payne, D; Rittenhouse, S; Singley, C, 2006)	0.33
" Ciprofloxacin and vancomycin were largely ineffective in attaining MIB90 concentrations within safe dosage ranges."	( In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Butcher, AR; Ha, KR; Psaltis, AJ; Tan, LW; Wormald, PJ, 2008)	0.66
" To treat skin infections such as impetigo, antibacterials with a short dosing schedule and low propensity to develop resistance should be used."	( Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. Tyring, SK; Weinberg, JM, 2010)	0.36

Role	Description
bacterial metabolite	Any prokaryotic metabolite produced during a metabolic reaction in bacteria.
antibacterial drug	A drug used to treat or prevent bacterial infections.
protein synthesis inhibitor	A compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
monocarboxylic acid	An oxoacid containing a single carboxy group.
oxanes	Any organic heteromonocyclic compoundthat is oxane or its substituted derivatives.
epoxide	Any cyclic ether in which the oxygen atom forms part of a 3-membered ring.
secondary alcohol	A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
triol	A chemical compound containing three hydroxy groups.
alpha,beta-unsaturated carboxylic ester	A carboxylic ester of general formula R(1)R(2)C=CR(3)-C(=O)OR(4) (R(4) =/= H) or R(1)C#C-C(=O)OR(2) (R(2) =/= H) in which the ester C=O function is conjugated to an unsaturated C-C bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
TDP1 protein	Homo sapiens (human)	Potency	1.0545	0.0008	11.3822	44.6684	AID686978; AID686979
IDH1	Homo sapiens (human)	Potency	4.6109	0.0052	10.8652	35.4813	AID686970
geminin	Homo sapiens (human)	Potency	0.2311	0.0046	11.3741	33.4983	AID624297
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	19.9526	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Isoleucyl-tRNA synthetase	Thermus thermophilus	Ki	0.2500	0.2500	0.2500	0.2500	AID977610
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Isoleucine--tRNA ligase	Escherichia coli K-12	Ki	0.0025	0.0025	0.0025	0.0025	AID629746
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
heat shock protein 90	Candida albicans	EC50 (µMol)	150.0000	0.1200	6.4855	33.8530	AID2423
streptokinase A precursor	Streptococcus pyogenes M1 GAS	EC50 (µMol)	0.2415	0.0600	8.9128	130.5170	AID1902; AID1914
Estrogen receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.4230	0.0060	22.3670	130.5170	AID1914
Estrogen receptor beta	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.4230	0.0060	22.3670	130.5170	AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
twin arginine protein translocation system - TatA protein	Escherichia coli str. K-12 substr. MG1655	AC50	4.9910	0.7070	10.9151	45.8560	AID504941
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
isoleucyl-tRNA aminoacylation	Isoleucine--tRNA ligase	Escherichia coli K-12
translation	Isoleucine--tRNA ligase	Escherichia coli K-12
tRNA aminoacylation for protein translation	Isoleucine--tRNA ligase	Escherichia coli K-12
isoleucyl-tRNA aminoacylation	Isoleucine--tRNA ligase	Escherichia coli K-12
response to antibiotic	Isoleucine--tRNA ligase	Escherichia coli K-12
aminoacyl-tRNA metabolism involved in translational fidelity	Isoleucine--tRNA ligase	Escherichia coli K-12
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
tRNA binding	Isoleucine--tRNA ligase	Escherichia coli K-12
aminoacyl-tRNA editing activity	Isoleucine--tRNA ligase	Escherichia coli K-12
aminoacyl-tRNA ligase activity	Isoleucine--tRNA ligase	Escherichia coli K-12
isoleucine-tRNA ligase activity	Isoleucine--tRNA ligase	Escherichia coli K-12
protein binding	Isoleucine--tRNA ligase	Escherichia coli K-12
ATP binding	Isoleucine--tRNA ligase	Escherichia coli K-12
zinc ion binding	Isoleucine--tRNA ligase	Escherichia coli K-12
metal ion binding	Isoleucine--tRNA ligase	Escherichia coli K-12
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
cytoplasm	Isoleucine--tRNA ligase	Escherichia coli K-12
cytosol	Isoleucine--tRNA ligase	Escherichia coli K-12
cytosol	Isoleucine--tRNA ligase	Escherichia coli K-12
cytosol	L-cysteine:1D-myo-inositol 2-amino-2-deoxy-alpha-D-glucopyranoside ligase	Mycobacterium tuberculosis H37Rv
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (270)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID565190	Antimicrobial activity against Staphylococcus aureus ATCC 29213 infected BALB/c mouse at 2 % administered topically 4 hrs post infection twice a day for 5 days	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID571440	Ratio of the MIC for Escherichia coli IH3080 in the absence of NAB7061 to MIC for Escherichia coli IH3080 in the presence of 4 ug/ml of NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1161173	Antimicrobial activity against Staphylococcus aureus isolate SWEETING after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID534122	Antibacterial activity against Streptococcus viridans	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID534120	Antibacterial activity against Streptococcus agalactiae	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID395161	Antibacterial activity against Enterococcus faecium ATCC 10541 after 16 hrs at 36 degC by microdilution method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.
AID373750	Antimicrobial activity against mupirocin-resistant methicillin-resistant Staphylococcus aureus assessed as resistant rate by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID574545	Antimicrobial activity against community-associated methicillin-resistant Staphylococcus aureus USA300	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.
AID67897	compound was tested for antibacterial activity against Ent. faecalis I	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID545929	Antimicrobial activity against Enterobacter cloacae ATCC 23355 by Etest method in presence of 4 ug/ml NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID392208	Antibacterial activity against Staphylococcus aureus ATCC 29213	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID1866115	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 incubated for 18 to 24 hrs by broth dilution method	2022	Journal of natural products, 03-25, Volume: 85, Issue:3	Cladobotric Acids: Metabolites from Cultures of
AID1853481	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 assessed as fold increase in MIC incubated for 30 days by resistance development based broth microdilution assay	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	SF
AID395158	Antibacterial activity against Staphylococcus aureus SP-N2 after 16 hrs at 36 degC by microdilution method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID125102	compound was tested for antibacterial activity against Moraxella catarrhalis 1502.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID86136	Minimal inhibitory concentration against Haemophilus influenzae Q1	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	The chemistry of Pseudomonic acid. 15. Synthesis and antibacterial activity of a series of 5-alkyl, 5-alkenyl, and 5-heterosubstituted oxazoles.
AID629748	Antibacterial activity against Escherichia coli	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Aminoacyl-tRNA synthetase inhibitors as potential antibiotics.
AID1563640	Antibacterial activity against methicillin-resistant Staphylococcus aureus infected in BALB/c mouse model of skin infection assessed as bacterial load in skin lesions at 2 mg administered topically as ointment twice daily for 7 days and measured at 24 hrs	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1161170	Antimicrobial activity against Staphylococcus aureus isolate RN4220 pmz1 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID1161177	Antimicrobial activity against Staphylococcus aureus isolate NEQAS 4026 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID545936	Ratio of MIC for Escherichia coli IH3080 to MIC for Escherichia coli IH3080 in presence of 4 ug/ml of NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1896845	Antibacterial activity against methicillin-resistant Staphylococcus aureus 252 assessed as prevention of visible growth by broth microdilution method
AID534113	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID565000	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID629746	Competitive inhibition of Escherichia coli Isoleucyl-tRNA synthetase	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Aminoacyl-tRNA synthetase inhibitors as potential antibiotics.
AID571446	Ratio of the MIC for Klebsiella pneumoniae ATCC 13883 in the absence of NAB7061 to MIC for Klebsiella pneumoniae ATCC 13883 in the presence of 4 ug/ml of NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID373747	Antimicrobial activity against mupirocin-susceptible methicillin-resistant Staphylococcus aureus by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID533664	Antimicrobial activity against Staphylococcus aureus RN1024-tms	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID534119	Antibacterial activity against beta-hemolytic Streptococcus group G	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID574554	Decrease in PSMbeta1 levels in Staphylococcus aureus USA300 at subinhibitory concentration after 24 hrs by RP-HPLC/ESI-MS	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.
AID91630	Minimum inhibitory concentration against Staphylococcus aureus 11481	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID574551	Decrease in delta toxin levels in Staphylococcus aureus Sanger 252 at subinhibitory concentrations after 24 hrs by RP-HPLC/ESI- MS	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.
AID1161162	Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID1896847	Antibacterial activity against Staphylococcus aureus ATCC29213 assessed as prevention of visible growth by broth microdilution method
AID577646	Antibacterial activity against methicillin-resistant Staphylococcus aureus harboring 41.7-kilobase conjugative staphylococcal multiresistance plasmid pPR9 conferring high-level mupirocin resistance	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Complete nucleotide sequence and comparative analysis of pPR9, a 41.7-kilobase conjugative staphylococcal multiresistance plasmid conferring high-level mupirocin resistance.
AID323906	Antibacterial activity against Staphylococcus aureus RN4220 with rplC S158L mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.
AID207530	Minimal inhibitory concentration against Staphylococcus aureus Oxford NCTC 6571	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	The chemistry of Pseudomonic acid. 15. Synthesis and antibacterial activity of a series of 5-alkyl, 5-alkenyl, and 5-heterosubstituted oxazoles.
AID323910	Antibacterial activity against Staphylococcus aureus RN4220 with rplC G152D, D159Y and G144R mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID565179	Antimicrobial activity against Staphylococcus aureus 8235 by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID373748	Antimicrobial activity against mupirocin-resistant methicillin-resistant Staphylococcus aureus by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID534116	Antibacterial activity against methicillin sensitive Staphylococcus aureus	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID1866117	Antimicrobial activity against heterogeneous vancomycin-intermediate -resistant Staphylococcus aureus 21773 incubated for 18 to 24 hrs by broth dilution method	2022	Journal of natural products, 03-25, Volume: 85, Issue:3	Cladobotric Acids: Metabolites from Cultures of
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID564999	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID565181	Antimicrobial activity against Staphylococcus aureus isolate 8235 at >200 ug/ml by microdilution method in presence of 50 % human serum	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID1161175	Antimicrobial activity against Staphylococcus aureus isolate CL 938 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID1161172	Antimicrobial activity against Staphylococcus aureus isolate Smith ATCC 13709 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1161176	Antimicrobial activity against Staphylococcus aureus isolate MN 1255 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID395156	Antibacterial activity against Staphylococcus aureus GIORGIO after 16 hrs at 36 degC by microdilution method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.
AID209766	Minimum inhibitory concentration against Streptococcus pyogenes Dig 7	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Benzo[f]naphtyridones: a new family of topical antibacterial agents active on multi-resistant Gram-positive pathogens.
AID375938	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 24 hrs by broth microdilution method	2006	Journal of natural products, Apr, Volume: 69, Issue:4	Antibacterial, partially acetylated oligorhamnosides from Cleistopholis patens.
AID1161179	Antimicrobial activity against Staphylococcus aureus isolate PAV 5 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID565183	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 grown as biofilms by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID323905	Antibacterial activity against Staphylococcus aureus RN4220 with rplC G155R mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1563643	Antibacterial activity against methicillin-resistant Staphylococcus aureus infected in BALB/c mouse model of skin wound assessed as retainment of dermis layers at 2 mg administered topically as ointment twice daily for 7 days and measured and after 24 hrs	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID565001	Antimicrobial activity against mupirocin- and methicillin-resistant Staphylococcus aureus by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1161183	Antimicrobial activity against Staphylococcus aureus isolate 68/8684 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID412492	Antibacterial activity against Enterococcus faecalis ATCC 29212 at 30 nmol after 16 to 20 hrs	2009	Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1	Antibacterial 5'-O-(N-dipeptidyl)-sulfamoyladenosines.
AID206020	Minimum inhibitory concentration against Staphylococcus aureus C 7	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID534121	Antibacterial activity against Streptococcus pyogenes	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID209610	In vitro antibacterial activity against Streptococcus pyogenes CN10	1999	Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13	Synthesis and antibacterial properties of beta-diketone acrylate bioisosteres of pseudomonic acid A.
AID534128	Antibacterial activity against Enterococcus species	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID477409	Antibacterial activity against Staphylococcus aureus NCTC 8325 after 16 to 20 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID571445	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 4 ug/ml NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID565187	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID163444	compound was tested for antibacterial activity against Pseudomonas aeruginosa K799 wt.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID1563641	Antibacterial activity against methicillin-resistant Staphylococcus aureus infected in BALB/c mouse model of skin wound assessed as reduction in appearance of secondary scald at 2 mg administered topically as ointment twice daily for 7 days and measured a	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID325104	Antibacterial activity against Staphylococcus aureus with ileS gene mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Transient loss of high-level mupirocin resistance in Staphylococcus aureus due to MupA polymorphism.
AID206624	compound was tested for antibacterial activity against Staphylococcus aureus F 89.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID412493	Antibacterial activity against wild type Escherichia coli at 30 nmol after 16 to 20 hrs	2009	Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1	Antibacterial 5'-O-(N-dipeptidyl)-sulfamoyladenosines.
AID41283	compound was tested for antibacterial activity against Bacteroides fragilis NCTC 10581.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID533663	Antimicrobial activity against Staphylococcus aureus RN1024	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID1634707	Antibacterial activity against vancomycin/methicillin-sensitive Staphylococcus aureus ATCC 25923 assessed as bacterial growth inhibition after 24 hrs by broth dilution method	2016	Journal of natural products, Apr-22, Volume: 79, Issue:4	Domino Synthesis of Embelin Derivatives with Antibacterial Activity.
AID94064	compound was tested for antibacterial activity against Klebsiella pneumoniae E70.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID545937	Ratio of MIC for Klebsiella pneumoniae ATCC 13883 to MIC for Klebsiella pneumoniae ATCC 13883 in presence of 4 ug/ml of NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1855560	Cytotoxicity against human HDFa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation.
AID571437	Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of 1 ug/ml NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID534117	Antibacterial activity against vancomycin intermediate Staphylococcus aureus	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID525143	Antimicrobial activity against linezolid-resistant Staphylococcus aureus isolate 004-737X expressing cfr and ermA gene isolated from paraplegic patient by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.
AID565180	Therapeutic index, ratio of IC50 for human CCD-32Sk cells to MIC for Staphylococcus aureus 8235	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID83646	compound was tested for antibacterial activity against Haemophilus influenzae Q1.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID206753	In vitro antibacterial activity against Staphylococcus aureus Oxford	1999	Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13	Synthesis and antibacterial properties of beta-diketone acrylate bioisosteres of pseudomonic acid A.
AID571449	Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of 1 ug/ml NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID412494	Antibacterial activity against Escherichia coli delta ABN mutant lacking peptidase A, B, N at 30 nmol after 16 to 20 hrs	2009	Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1	Antibacterial 5'-O-(N-dipeptidyl)-sulfamoyladenosines.
AID534118	Antibacterial activity against beta-hemolytic Streptococcus group C	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID1161164	Antimicrobial activity against Staphylococcus aureus isolate CARTER 37 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID279572	Antimicrobial activity against Salmonella enterica serovar Typhimurium JB1855 in Caenorhabditis elegans	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Caenorhabditis elegans as a model to determine fitness of antibiotic-resistant Salmonella enterica serovar typhimurium.
AID545933	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 4 ug/ml NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1161163	Antimicrobial activity against Staphylococcus aureus isolate A53 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID574546	Antimicrobial activity against community-associated methicillin-resistant Staphylococcus aureus Sanger 252	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.
AID91625	Inhibitory activity against isoleucyl-tRNA synthetase (IRS) of Staphylococcus aureus C 7	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID534115	Antibacterial activity against methicillin resistant Staphylococcus aureus	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID545939	Ratio of MIC for Acinetobacter baumannii ATCC 19606 to MIC for Acinetobacter baumannii ATCC 19606 in presence of 4 ug/ml of NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID571441	Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID323911	Antibacterial activity against Staphylococcus aureus RN4220 with rplC G152D, D159Y and G155R mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.
AID533662	Antimicrobial activity against Staphylococcus aureus RN4220 harboring vgaAv positive plasmid CU1	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID1161174	Antimicrobial activity against Staphylococcus aureus isolate CL 1033 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID1161186	Antimicrobial activity against Staphylococcus aureus isolate 934324 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID1161165	Antimicrobial activity against Staphylococcus aureus isolate CL 939 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID533660	Antimicrobial activity against Staphylococcus aureus RN4220 harboring plasmid VGA	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID197879	In vitro minimum inhibitory activity against Staphylococcus aureus Oxford strain	2002	Journal of medicinal chemistry, May-09, Volume: 45, Issue:10	Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens.
AID197987	In vitro minimum inhibitory activity against Staphylococcus aureus WCUH29 strain	2002	Journal of medicinal chemistry, May-09, Volume: 45, Issue:10	Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens.
AID1161178	Antimicrobial activity against Staphylococcus aureus isolate OGA833 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID408605	Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction upto 10 uM	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants.
AID395160	Antibacterial activity against methicillin-resistant Staphylococcus aureus KS2007-6 after 16 hrs at 36 degC by microdilution method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1563642	Antibacterial activity against methicillin-resistant Staphylococcus aureus infected in BALB/c mouse model of skin wound assessed as reduction in detachment of epidermis from dermis at 2 mg administered topically as ointment twice daily for 7 days and meas	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID571444	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 2 ug/ml NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID545938	Ratio of MIC for Enterobacter cloacae ATCC 23355 to MIC for Enterobacter cloacae ATCC 23355 in presence of 4 ug/ml of NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID206625	compound was tested for antibacterial activity against Staphylococcus aureus NCTC 6571.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID205558	Minimum inhibitory concentration against Staphylococcus aureus AS5155	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Benzo[f]naphtyridones: a new family of topical antibacterial agents active on multi-resistant Gram-positive pathogens.
AID534127	Antibacterial activity against gram-negative Bacilli species	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID395155	Antibacterial activity against Staphylococcus aureus ATCC 10537 after 16 hrs at 36 degC by microdilution method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.
AID571439	Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of 4 ug/ml NAB7064	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID565176	Antimicrobial activity against Streptococcus pyogenes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID565185	Antimicrobial activity against Staphylococcus epidermidis RP62A grown as biofilms by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID323908	Antibacterial activity against Staphylococcus aureus RN4220 with rplC G152D and D159Y mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.
AID545917	Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method in presence of 4 ug/ml NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1161190	Antimicrobial activity against Staphylococcus aureus isolate NEQAS 4158 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID533665	Antimicrobial activity against Staphylococcus aureus ATCC 29213	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID571434	Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of 4 ug/ml NAB7064	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID323913	Antibacterial activity against Staphylococcus aureus RN4220 with rplC G152D, D159Y, G155R and A150T mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.
AID1896843	Antibacterial activity against Shigella flexneri CMCC51572 assessed as prevention of visible growth by broth microdilution method
AID1862475	Induction of drug resistance in methicillin-resistant Staphylococcus aureus USA 300 assessed as fold increase in MIC treated daily for 30 days	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Membrane acting Povarov-Doebner derived compounds potently disperse preformed multidrug resistant Gram-positive bacterial biofilms.
AID340858	Antimicrobial activity against wild type vancomycin-intermediate resistant Staphylococcus aureus Mu50 by microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID574553	Decrease in PSMbeta1 levels in Staphylococcus aureus Sanger 252 at subinhibitory concentrations after 24 hrs by RP-HPLC/ESI- MS	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.
AID571432	Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of 1 ug/ml NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID534114	Antibacterial activity against methicillin sensitive coagulase-negative Staphylococcus	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.
AID205683	Minimum inhibitory concentration against Staphylococcus aureus RN4220	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Benzo[f]naphtyridones: a new family of topical antibacterial agents active on multi-resistant Gram-positive pathogens.
AID1866116	Antimicrobial activity against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus Mu50 incubated for 18 to 24 hrs by broth dilution method	2022	Journal of natural products, 03-25, Volume: 85, Issue:3	Cladobotric Acids: Metabolites from Cultures of
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID565186	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID1428626	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 by broth microdilution method	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
AID571442	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID86121	In vitro antibacterial activity against Haemophilus influenzae Q1	1999	Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13	Synthesis and antibacterial properties of beta-diketone acrylate bioisosteres of pseudomonic acid A.
AID574552	Decrease in delta toxin levels in Staphylococcus aureus USA300 at subinhibitory concentrations after 24 hrs by RP-HPLC/ESI- MS	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.
AID565188	Antimicrobial activity against Staphylococcus epidermidis RP62A by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID590639	Inhibition of Mycobacterium tuberculosis recombinant MBP-tagged MshC assessed as formation of fluorescently labeled Cys-GlcN-Ins by HPLC	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Susceptibility and mode of binding of the Mycobacterium tuberculosis cysteinyl transferase mycothiol ligase to tRNA synthetase inhibitors.
AID1161169	Antimicrobial activity against Staphylococcus aureus isolate MILES HALL after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID395162	Antibacterial activity against Enterococcus faecalis ATCC 19433 after 16 hrs at 36 degC by microdilution method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.
AID1161187	Antimicrobial activity against Staphylococcus aureus isolate 934334 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID571436	Antibacterial activity against Escherichia coli IH3080 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID571452	Ratio of the MIC for Enterobacter cloacae ATCC 23355 in the absence of NAB7061 to MIC for Enterobacter cloacae ATCC 23355 ATCC 13883 in the presence of 4 ug/ml of NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID323907	Antibacterial activity against Staphylococcus aureus RN4220 with rplC G152D mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.
AID1862476	Induction of drug resistance in methicillin-resistant Staphylococcus aureus ATCC 33592 assessed as fold increase in MIC treated daily for 30 days	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Membrane acting Povarov-Doebner derived compounds potently disperse preformed multidrug resistant Gram-positive bacterial biofilms.
AID70148	compound was tested for antibacterial activity against Escherichia coli DC0.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID571433	Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of 2 ug/ml NAB7062	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID340859	Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 graR mutant microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID395153	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 16 hrs at 36 degC by microdilution method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.
AID1909744	Invivo antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 infected in Balb/c mouse model assessed as reduction in bacterial infection in skin wounds administered topically twice daily 2 days post infection and measured after	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Mechanistic Studies and
AID323912	Antibacterial activity against Staphylococcus aureus RN4220 with rplC G152D, D159Y, G155R and H134N mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.
AID125084	In vitro antibacterial activity against Moraxella catarrhalis 1502	1999	Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13	Synthesis and antibacterial properties of beta-diketone acrylate bioisosteres of pseudomonic acid A.
AID66078	compound was tested for antibacterial activity against Ent. cloacae N1.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID209731	compound was tested for antibacterial activity against Strep. pneumoniae 1761.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID1161188	Antimicrobial activity against Staphylococcus aureus isolate 934335 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID571447	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID1161182	Antimicrobial activity against Staphylococcus aureus isolate 306 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID325106	Antibacterial activity against Staphylococcus aureus MB1348 with mupA gene mutation by Etest	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Transient loss of high-level mupirocin resistance in Staphylococcus aureus due to MupA polymorphism.
AID571450	Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of 2 ug/ml NAB7062	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID395154	Antibacterial activity against Staphylococcus aureus ATCC 6538P after 16 hrs at 36 degC by microdilution method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.
AID395159	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 16 hrs at 36 degC by microdilution method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.
AID279571	Antimicrobial activity against Salmonella enterica serovar Typhimurium JB1850 in Caenorhabditis elegans	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Caenorhabditis elegans as a model to determine fitness of antibiotic-resistant Salmonella enterica serovar typhimurium.
AID1161167	Antimicrobial activity against Staphylococcus aureus isolate Ealing 32 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID571448	Antibacterial activity against Enterobacter cloacae ATCC 23355 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID209637	Minimal inhibitory concentration against Streptococcus pyogenes CN10	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	The chemistry of Pseudomonic acid. 15. Synthesis and antibacterial activity of a series of 5-alkyl, 5-alkenyl, and 5-heterosubstituted oxazoles.
AID1563644	Antibacterial activity against methicillin-resistant Staphylococcus aureus infected in BALB/c mouse model of skin wound assessed as retainment of fat layers at 2 mg administered topically as ointment twice daily for 7 days and measured after 24 hrs by HE	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID545921	Antimicrobial activity against Escherichia coli IH3080 by Etest method in presence of 4 ug/ml NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID323903	Antibacterial activity against wild type Staphylococcus aureus RN4220	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.
AID91631	Inhibitory activity against isoleucyl-tRNA synthetase (IRS) of Staphylococcus aureus NCTC 6571	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID1909757	Toxicity in Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 assessed as necrosis administered topically twice daily 2 days post infection and measured after 5 days post compound treatment by H and E staining based histopathol	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Mechanistic Studies and
AID629747	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Aminoacyl-tRNA synthetase inhibitors as potential antibiotics.
AID206065	compound was tested for antibacterial activity aagainst Staphylococcus epidermidis PHLN 20.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID373749	Antimicrobial activity against mupirocin-susceptible methicillin-resistant Staphylococcus aureus assessed as resistant rate by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID375939	Antibacterial activity against methicillin-resistant Staphylococcus aureus 78-13607A after 24 hrs by broth microdilution method	2006	Journal of natural products, Apr, Volume: 69, Issue:4	Antibacterial, partially acetylated oligorhamnosides from Cleistopholis patens.
AID571443	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 1 ug/ml NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID206623	compound was tested for antibacterial activity against Staphylococcus aureus C 37.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID1896860	Bacteriostatic effect against methicillin-resistant Staphylococcus aureus 252 assessed as decrease in CFU/ml at MIC measured for 24 hrs by CLSI based time-kill kinetic assays
AID325105	Antibacterial activity against Staphylococcus aureus J2870 with mupA gene mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Transient loss of high-level mupirocin resistance in Staphylococcus aureus due to MupA polymorphism.
AID574550	Decrease in PSMalpha levels in Staphylococcus aureus Sanger 252 at subinhibitory concentrations after 24 hrs by RP-HPLC/ESI- MS	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.
AID209931	compound was tested for antibacterial activity against Streptococcus pyogenes CN10.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID91623	Inhibitory activity against isoleucyl-tRNA synthetase (IRS) of Staphylococcus aureus 11481	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID395163	Antibacterial activity against Enterococcus faecalis ATCC 29212 after 16 hrs at 36 degC by microdilution method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.
AID525144	Antimicrobial activity against Staphylococcus epidermidis isolate 426-3147L expressing cfr gene by broth microdilution CLSI method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.
AID533661	Antimicrobial activity against Staphylococcus aureus RN4220 harboring plasmid CU1	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID571453	Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID565184	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 grown as biofilms by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1482267	Antibacterial activity against Escherichia coli MG1655 measured every 15 mins for 12 hrs	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.
AID340860	Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 vraG mutant microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID1896842	Antibacterial activity against Escherichia coli ATCC25922 assessed as prevention of visible growth by broth microdilution method
AID91620	Inhibition concentration against Isoleucyl-tRNA synthetase from Staphylococcus aureus NCTC 6571	1997	Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16	The chemistry of pseudomonic acid. 18. Heterocyclic replacement of the alpha,beta-unsaturated ester: synthesis, molecular modeling, and antibacterial activity.
AID1161166	Antimicrobial activity against Staphylococcus aureus isolate Ealing 23 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID323909	Antibacterial activity against Staphylococcus aureus RN4220 with rplC G152D and G155R mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.
AID206627	minimum inhibitory concentration (MIC) against Staphylococcus aureus NCTC 6571.	1997	Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16	The chemistry of pseudomonic acid. 18. Heterocyclic replacement of the alpha,beta-unsaturated ester: synthesis, molecular modeling, and antibacterial activity.
AID64380	In vitro minimum inhibitory activity against Enterococcus faecalis 7 strain	2002	Journal of medicinal chemistry, May-09, Volume: 45, Issue:10	Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1161185	Antimicrobial activity against Staphylococcus aureus isolate 929035 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID1161181	Antimicrobial activity against Staphylococcus aureus isolate RN1030 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID162891	compound was tested for antibacterial activity against Pr. mirabilis C889.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID571451	Antibacterial activity against Enterobacter cloacae ATCC 23355 ATCC 13883 by Etest method in presence of 4 ug/ml NAB7064	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID571438	Antibacterial activity against Escherichia coli IH3080 by Etest method in presence of 2 ug/ml NAB7062	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID545925	Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 4 ug/ml NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID325107	Antibacterial activity against Staphylococcus aureus MB1348 with mupA gene mutation by broth microdilution	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Transient loss of high-level mupirocin resistance in Staphylococcus aureus due to MupA polymorphism.
AID1909756	Toxicity in Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 assessed as hemorrhage administered topically twice daily 2 days post infection and measured after 5 days post compound treatment by H and E staining based histopath	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Mechanistic Studies and
AID1909758	Toxicity in Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 assessed as chronic inflammatory response administered topically twice daily 2 days post infection and measured after 5 days post compound treatment by H and E stain	2022	Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9	Mechanistic Studies and
AID574549	Decrease in PSMalpha levels in Staphylococcus aureus USA300 at subinhibitory concentration after 24 hrs by RP-HPLC/ESI-MS	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.
AID1896844	Antibacterial activity against Salmonella typhi CMCC50094 assessed as prevention of visible growth by broth microdilution method
AID1161171	Antimicrobial activity against Staphylococcus aureus isolate RUSSELL after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID1493822	Antibacterial activity against Staphylococcus aureus RN4220 NRS107 clinical isolate after 18 to 20 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Biphenylthiazole antibiotics with an oxadiazole linker: An approach to improve physicochemical properties and oral bioavailability.
AID323904	Antibacterial activity against Staphylococcus aureus RN4220 with rplC D159Y mutation	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.
AID1161184	Antimicrobial activity against Staphylococcus aureus isolate 929003 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID395157	Antibacterial activity against Staphylococcus aureus Smith after 16 hrs at 36 degC by microdilution method	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.
AID1896848	Antibacterial activity against Staphylococcus aureus ATCC25923 assessed as prevention of visible growth by broth microdilution method
AID477411	Antibacterial activity against MBX-1090-resistant Staphylococcus aureus isolate d20A1 after 16 to 20 hrs by broth microdilution method	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID125087	Minimal inhibitory concentration of compound against Moraxella catarrhalis 1502	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	The chemistry of Pseudomonic acid. 15. Synthesis and antibacterial activity of a series of 5-alkyl, 5-alkenyl, and 5-heterosubstituted oxazoles.
AID533659	Antimicrobial activity against Staphylococcus aureus RN4220	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID208155	Minimal inhibitory concentration against Streptococcus pneumoniae PU7	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	The chemistry of Pseudomonic acid. 15. Synthesis and antibacterial activity of a series of 5-alkyl, 5-alkenyl, and 5-heterosubstituted oxazoles.
AID571435	Ratio of the MIC for Escherichia coli ATCC 25992 in the absence of NAB7061 to MIC for Escherichia coli ATCC 25992 in the presence of 4 ug/ml of NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID571203	Antibacterial activity against Escherichia coli ATCC 25992 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID1161180	Antimicrobial activity against Staphylococcus aureus isolate RN1024 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID64379	In vitro minimum inhibitory activity against Enterococcus faecalis 1 strain	2002	Journal of medicinal chemistry, May-09, Volume: 45, Issue:10	Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID545935	Ratio of MIC for Escherichia coli ATCC 25922 to MIC for Escherichia coli ATCC 25922 in presence of 4 ug/ml of NAB741	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1896846	Antibacterial activity against methicillin-resistant Staphylococcus aureus R3708 assessed as prevention of visible growth by broth microdilution method
AID565178	Cytotoxicity against human CCD-32Sk cells after 48 hrs by MTT assay	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID571200	Antibacterial activity against Escherichia coli ATCC 25992 by Etest method in presence of NAB7061	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID210390	In vitro antibacterial activity against Streptococcus pneumoniae PU7	1999	Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13	Synthesis and antibacterial properties of beta-diketone acrylate bioisosteres of pseudomonic acid A.
AID412491	Antibacterial activity against Staphylococcus aureus ATCC 25923 at 30 nmol after 16 to 20 hrs	2009	Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1	Antibacterial 5'-O-(N-dipeptidyl)-sulfamoyladenosines.
AID1161189	Antimicrobial activity against Staphylococcus aureus isolate 934387 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID1161168	Antimicrobial activity against Staphylococcus aureus isolate F89 after 24 hrs by broth microdilution method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID70149	compound was tested for antibacterial activity against Escherichia coli DC2.	1996	Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.
AID1634708	Antibacterial activity against vancomycin-intermediate/methicillin-resistant Staphylococcus aureus NRS402 assessed as bacterial growth inhibition after 24 hrs by broth dilution method	2016	Journal of natural products, Apr-22, Volume: 79, Issue:4	Domino Synthesis of Embelin Derivatives with Antibacterial Activity.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1811	Experimentally measured binding affinity data derived from PDB	2001	The Journal of biological chemistry, Dec-14, Volume: 276, Issue:50	Structural basis for the recognition of isoleucyl-adenylate and an antibiotic, mupirocin, by isoleucyl-tRNA synthetase.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2001	The Journal of biological chemistry, Dec-14, Volume: 276, Issue:50	Structural basis for the recognition of isoleucyl-adenylate and an antibiotic, mupirocin, by isoleucyl-tRNA synthetase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	85 (6.50)	18.7374
1990's	242 (18.50)	18.2507
2000's	358 (27.37)	29.6817
2010's	486 (37.16)	24.3611
2020's	137 (10.47)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	214 (15.27%)	5.53%
Reviews	140 (9.99%)	6.00%
Case Studies	102 (7.28%)	4.05%
Observational	9 (0.64%)	0.25%
Other	936 (66.81%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (68)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) [NCT00626795]	Phase 2	773 participants (Actual)	Interventional	2008-02-29	Completed
Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the United States [NCT01153880]		1 participants (Actual)	Observational	2008-12-31	Completed
Treating Parents to Reduce Neonatal Intensive Care Unit (NICU) Transmission of Staphylococcus Aureus [NCT02223520]		307 participants (Actual)	Interventional	2014-11-30	Completed
Detection, Education, Research and Decolonization Without Isolation in Long-term Care to Control(DERAIL)MRSA [NCT01302210]		22,302 participants (Actual)	Observational	2010-10-31	Completed
Topical Antibiotics in Chronic Rhinosinusitis [NCT03673956]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2018-09-26	Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the European Union [NCT01153828]		1 participants (Actual)	Observational	2008-11-30	Completed
Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery: a Prospective Randomized Controlled Trial - 2 Year Outcome in Prosthetic Surgery [NCT03962907]	Phase 4	1,318 participants (Actual)	Interventional	2019-01-01	Completed
Prospective Study on the Incidence, Predictors, and Characteristics of Methicillin-Resistant Staphylococcus Aureus Infections and a Randomized, Double-Blind Study on Decolonization Procedures for Prevention of MRSA Infections Among HIV-Infected Persons [NCT00631566]		550 participants (Actual)	Interventional	2007-05-31	Completed
Prospective, Randomized, Open-Label Study of Topical Antibiotic Prophylaxis at the Catheter Exit Site: Continuous Daily Gentamicin Cream Versus Cyclical Gentamicin Cream and Mupirocin 2% Cream Alternating at Monthly Basis. [NCT00751374]	Phase 4	500 participants (Anticipated)	Interventional	2008-09-30	Not yet recruiting
Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans [NCT04218799]	Phase 4	19 participants (Actual)	Interventional	2014-08-12	Completed
Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection [NCT02267122]	Phase 3	147 participants (Actual)	Interventional	2012-01-31	Completed
MESS- MRSA Eradication Study Skåne. A Comparison Between Systemic Antibiotic Treatment in Combination With Topical Mupirocintreatment With Only Topical Mupiroicintreatment to Eradicate MRSA in Throat Carriers [NCT01269541]		69 participants (Actual)	Interventional	2011-03-01	Completed
[NCT01152593]		400 participants (Anticipated)	Interventional	2010-07-31	Not yet recruiting
Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization [NCT04222699]	Phase 4	58 participants (Actual)	Interventional	2012-09-18	Completed
The Effect of Mupirocin 2% Ointment on the Duration of Stay of Temporary Hemodialysis Catheter Compared to Other Spray Antibiotics [NCT05874219]	Phase 2/Phase 3	150 participants (Actual)	Interventional	2023-04-10	Completed
Effects of Topical Gentamicin on the Prevention of Peritoneal Dialysis Related Infection Caused by Pseudomonas Aeruginosa [NCT05251584]		60 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Efficacy and Safety of Local Application of Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection: A Double-Blind, Stratified Randomized Controlled Trial [NCT02547103]	Phase 4	354 participants (Anticipated)	Interventional	2016-06-01	Recruiting
Bacterial Decolonization to Prevent Radiation Dermatitis: A Randomized Controlled Trial and Quality of Life Assessment [NCT03883828]	Phase 2/Phase 3	80 participants (Actual)	Interventional	2019-06-03	Completed
A 2X2 Phase III Open-label Clinical Trial of Therapy for Patients With Recurrent Methicillin Resistant Staphylococcus Aureus Infections: Topical Nasal & Body Decolonization and/or Environmental Decontamination vs. Standard of Care [NCT00560599]	Phase 3	350 participants (Anticipated)	Interventional	2007-04-30	Completed
Intermittent Mupirocin to Prevent Staphylococcal Infection [NCT00108160]	Phase 4	146 participants (Actual)	Interventional	2005-04-30	Completed
The Use of Mupirocin Dressings and Its Effect on Surgical Site Infections in Elective Colorectal Surgery: A Prospective, Randomized Controlled Trial [NCT02619773]		150 participants (Actual)	Interventional	2015-11-30	Completed
Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial (DECO-SSI Trial) [NCT02560155]		1,300 participants (Actual)	Interventional	2015-11-30	Completed
Ph-III Randomized, Multicentric, Controlled , Non-inferiority Trial to Evaluate the Safety and Efficacy of Mupirocin Gel 20 mg/g Versus Mupirocin Ointment 20 mg/g and Placebo in the Treatment of Impetigo in Paediatric Population [NCT04287777]	Phase 3	467 participants (Actual)	Interventional	2014-02-28	Completed
Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection [NCT00801879]	Phase 4	100 participants (Actual)	Interventional	2003-09-30	Completed
Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence [NCT02566928]	Phase 4	278 participants (Anticipated)	Interventional	2015-10-31	Recruiting
Clinical Trial to Compare the Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by MRSA (Methicillin Resistant Staphylococcus Aureus) [NCT01400308]	Phase 4	99 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to The differences seen between treatments led to recalculation of the sample, unattainable in a reasonable time)
The Efficacy of Timolol 0.5% Gel Forming Solution for the Treatment of Ulcerated Hemangiomas [NCT01408056]	Phase 2	0 participants (Actual)	Interventional	2011-02-28	Withdrawn(stopped due to Difficulty with recruitment)
A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Mupirocin Calcium Cream, 2% and Reference Listed Bactroban® Cream (Mupirocin Calcium Cream, 2%) and Compare Both Activ [NCT01876550]	Phase 1	1,902 participants (Actual)	Interventional	2013-02-28	Completed
Household vs. Individual Approach to Decolonization of Community-acquired Methicillin-resistant Staphylococcus Aureus. [NCT00731783]		183 participants (Actual)	Interventional	2008-07-31	Completed
Community-Acquired Methicillin Resistant Staphylococcus Aureus (CA-MRSA) Vaginal and Nasal Colonization in Pregnant Women and Frequency of CA-MRSA Infections in Previously Healthy Term and Near-Term Neonates [NCT00532324]		1,500 participants (Anticipated)	Interventional	2008-01-31	Recruiting
Investigation of the Influence of Intranasal Mupirocin on the Prevalence of S. Aureus Nosocomial Infections by Eradication of Intranasal S. Aureus [NCT00156377]	Phase 4	1,200 participants	Interventional	2002-11-30	Completed
A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections [NCT01049438]		31 participants (Actual)	Interventional	2006-08-31	Completed
[NCT01918813]		662 participants (Actual)	Interventional	2009-11-30	Completed
[NCT01943136]	Phase 1	128 participants (Anticipated)	Interventional	2013-08-31	Recruiting
MIR-CABG: A Randomized, Double-blind, Placebo-controlled, Single-Center Study to Evaluate the Impact of Mupirocin on Infection Rate Post Coronary Artery Bypass Grafting [NCT01949935]	Phase 3	974 participants (Actual)	Interventional	2009-03-31	Completed
Antimicrobial Photodynamic Therapy in the Nasal Decolonization of Maintenance Hemodialysis Patients: A Pilot Randomized Trial [NCT04047914]		34 participants (Actual)	Interventional	2019-11-01	Completed
Comparison of Decolonization of MRSA Using Theraworx [NCT00713674]		0 participants (Actual)	Interventional	2008-03-31	Withdrawn(stopped due to Lack of patient recruitment.)
Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal [NCT00980980]		74,256 participants (Actual)	Interventional	2009-09-30	Completed
Treatment of Nasal Staphylococcus Aureus Colonization in Patients With Hereditary Hemorrhagic Telangiectasia With Recurrent Epistaxis. [NCT02963129]	Phase 3	40 participants (Anticipated)	Interventional	2017-06-30	Not yet recruiting
A Randomized, Double-Blind Controlled Trial of Monolaurin Ointment Versus Mupirocin Ointment of Bacterial Skin Infections Among Pediatric Patients 5-18 Years Old in Community-Based Setting [NCT06046937]	Early Phase 1	40 participants (Actual)	Interventional	2023-06-01	Completed
An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus Infection in Soldiers: a Controlled Trial [NCT00289588]		3,000 participants	Interventional	2005-01-31	Completed
A Randomized Controlled Double Blind Study Using Mupirocin Versus Polysporin Triple for the Prevention of Catheter-related Infections in Patients Treated With Peritoneal Dialysis [NCT00400595]	Phase 4	200 participants (Actual)	Interventional	2006-02-28	Completed
Assessment of Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery Using Intranasal Mupirocin Ointment [NCT00406913]		37 participants (Actual)	Interventional	2005-10-31	Completed
Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine [NCT01313182]	Phase 4	1,874 participants (Actual)	Interventional	2011-03-31	Completed
Cluster-randomized Non-inferiority Trial Comparing Mupirocin vs Iodophor for Nasal Decolonization of ICU Patients to Assess Impact on S. Aureus Clinical Cultures and All-cause Bloodstream Infection During Routine Chlorhexidine Bathing [NCT03140423]	Phase 4	137 participants (Actual)	Interventional	2017-05-01	Active, not recruiting
The Natural History of Community-Associated Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections and an Evaluation of Decolonization Strategies [NCT00513799]		300 participants (Actual)	Interventional	2007-03-31	Completed
Randomized Controlled Trial of Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a Neonatal Intensive Care Unit [NCT02967432]	Phase 2	216 participants (Actual)	Interventional	2016-10-31	Completed
Integrating Personal and Household Environmental Hygiene Measures to Prevent Methicillin-Resistant Staphylococcus Aureus Infection [NCT02572791]	Phase 4	835 participants (Actual)	Interventional	2015-10-31	Active, not recruiting
Stop Community MRSA Colonization Among Patients (SUSTAIN) [NCT02029872]	Phase 4	77 participants (Actual)	Interventional	2014-01-31	Completed
The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis [NCT00179959]	Phase 4	31 participants (Actual)	Interventional	2005-09-30	Completed
Checklist to Prevent MRSA Surgical Site Infections [NCT02216227]		1,794 participants (Actual)	Interventional	2014-04-01	Completed
Methicillin-resistant Staphylococcus Aureus in a Trauma Population: Does Decolonization Prevent Infection? [NCT01820455]		55 participants (Actual)	Interventional	2012-01-31	Completed
Randomized Controlled Trial of Chlorhexidine Gluconate, Intranasal Mupirocin, Rifampin and Doxycycline Versus Chlorhexidine Gluconate and Intranasal Mupirocin Alone for the Eradication of Methicillin-resistant Staphylococcus Aureus Among an Ambulatory Pat [NCT01438515]		100 participants (Actual)	Interventional	2008-08-31	Completed
A Single Centre, Open, Non-controlled Study in Healthy Subjects to Assess the Eradication of Nasal Carriage of Staphylococcus Aureus (SA) Following a Five Day Course of Mupirocin (Bactroban 2% Nasal Ointment) Using a Broth Enriched Culture Microbiological [NCT02284555]	Phase 4	12 participants (Actual)	Interventional	2014-08-31	Completed
Decolonization to Reduce After-Surgery Events of Surgical Site Infection [NCT05586776]	Phase 4	2,700 participants (Anticipated)	Interventional	2023-01-17	Recruiting
Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe) [NCT01349192]	Phase 2	47 participants (Actual)	Interventional	2011-04-30	Terminated(stopped due to Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects)
A Randomized Trial to Evaluate a Staphylococcus Eradication Protocol for Patients Who Present to the Emergency Department With Cutaneous Abscess [NCT01537783]	Phase 4	50 participants (Actual)	Interventional	2011-09-30	Completed
Comparison of Post op Outcomes in Endoscopic Sinus Surgery Using Varying Nasal Sinus Irrigations. Saline vs. Saline and Budesonide vs Saline, Budesonide, and Culture Directed Topical Antibiotics [NCT03303677]	Phase 3	0 participants (Actual)	Interventional	2018-04-01	Withdrawn(stopped due to Withdrawn by sponsor)
Persistent MRSA Eradication Protocol (PMEP) [NCT01594827]	Phase 2	29 participants (Actual)	Interventional	2012-10-31	Completed
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) [NCT03489629]	Phase 2	42 participants (Anticipated)	Interventional	2018-04-03	Recruiting
The Use of Antibiotic Sinonasal Rinse After Sinus Surgery: A Randomized Double-Blind Control Trial [NCT02218307]	Phase 4	68 participants (Actual)	Interventional	2011-11-30	Completed
Evaluation of the Efficacy of Follicles-derived Microtissue Homogenate in Promoting Wound Healing After Hair Transplantation [NCT05839158]		100 participants (Actual)	Interventional	2022-03-01	Completed
Individualized vs. Household Eradication of MRSA in Households With Children [NCT01814371]		474 participants (Actual)	Interventional	2013-04-30	Completed
Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis: A Randomized Controlled Trial and Quality of Life Assessment [NCT05893810]	Phase 3	176 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Safety and Efficacy of Intranasal and Topical Mupirocin in Eradicating Colonization With Staphylococcus Aureus (SA) in Critically Ill Infants - a Phase 2, Multi-Center, Open Label, Randomized Trial [NCT01827358]	Phase 2	155 participants (Actual)	Interventional	2014-04-30	Completed
Long-term StaphyloCoccus Aureus decolonizAtion in Patients on Home parenteRal nutRition: a randomIzed multicEnter tRial. [NCT03173053]		63 participants (Actual)	Interventional	2018-02-08	Terminated(stopped due to Results interim-analysis)
Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo's Mupirocin Cream to A Reference Manufacturer's Mupirocin Cream and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily [NCT04155203]	Phase 3	657 participants (Actual)	Interventional	2019-10-15	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00108160 (3) [back to overview]	Acquisition of New S. Aureus Strains
NCT00108160 (3) [back to overview]	Re-infection With S. Aureus
NCT00108160 (3) [back to overview]	S. Aureus Re-infections (New or Recurrent)
NCT00179959 (1) [back to overview]	Change in Eczema Area and Severity Index (EASI)Scores According to Location
NCT00513799 (3) [back to overview]	Number of Participants Eradicated of S. Aureus Carriage - 1 Month After Intervention
NCT00513799 (3) [back to overview]	Number of Participants Eradicated of S. Aureus Carriage - 4 Months After Intervention
NCT00513799 (3) [back to overview]	Number of Participants With Recurrent Staphylococcus Aureus Skin or Soft Tissue Infection
NCT00626795 (3) [back to overview]	Participants With Clinical Cure According to Investigator's Assessment.
NCT00626795 (3) [back to overview]	Participants With Bacteriological Cure According to Bacteriological Samples
NCT00626795 (3) [back to overview]	Participants With Clinical and Bacteriological Cure According to Investigator's Assessment and Bacteriological Samples
NCT00631566 (2) [back to overview]	The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA Colonization
NCT00631566 (2) [back to overview]	To Determine the Prevalence and Incidence of MRSA Colonization of the Nares, Throat, Perirectal, Axilla, and Groin Areas Among HIV Infected Patients and to Study Changes in the Colonization Rates Over Time.
NCT00731783 (8) [back to overview]	Number of Index Patients Eradicated of S. Aureus Carriage - 3 Month After Performing Decolonization Measures
NCT00731783 (8) [back to overview]	Number of Index Patients Eradicated of S. Aureus Carriage - 1 Month After Performing Decolonization Measures
NCT00731783 (8) [back to overview]	Number of Index Patients Eradicated of S. Aureus Carriage - 12 Month After Performing Decolonization Measures
NCT00731783 (8) [back to overview]	Number of Index Patients Eradicated of S. Aureus Carriage - 6 Month After Performing Decolonization Measures
NCT00731783 (8) [back to overview]	Recurrence of CA-MRSA Skin or Soft Tissue Infection - 1 Month After Enrollment.
NCT00731783 (8) [back to overview]	Recurrence of CA-MRSA Skin or Soft Tissue Infection - 12 Month After Enrollment.
NCT00731783 (8) [back to overview]	Recurrence of CA-MRSA Skin or Soft Tissue Infection - 3 Month After Enrollment.
NCT00731783 (8) [back to overview]	Recurrence of CA-MRSA Skin or Soft Tissue Infection - 6 Month After Enrollment.
NCT00980980 (8) [back to overview]	Blood Culture Contamination Rates
NCT00980980 (8) [back to overview]	Intervention Impact on Bacteriuria and Candiduria
NCT00980980 (8) [back to overview]	Intervention Impact on Healthcare Costs
NCT00980980 (8) [back to overview]	Intervention Impact on Mupirocin Susceptibility of MRSA Isolates
NCT00980980 (8) [back to overview]	ICU-attributable All-pathogen Bloodstream Infection
NCT00980980 (8) [back to overview]	Intervention Impact on Chlorhexidine Susceptibility of MRSA Isolates
NCT00980980 (8) [back to overview]	Main Outcome: Patients With Nosocomial MRSA Clinical Cultures
NCT00980980 (8) [back to overview]	MRSA Bloodstream Infection
NCT01313182 (2) [back to overview]	Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.
NCT01313182 (2) [back to overview]	Surgical Site Infections Occurring Within 12 Months of Surgical Procedure
NCT01349192 (4) [back to overview]	Pulmonary Exacerbations
NCT01349192 (4) [back to overview]	Antibiotic Use (Days of Use Per Subject)
NCT01349192 (4) [back to overview]	Antibiotic Use (Proportion of Subjects)
NCT01349192 (4) [back to overview]	MRSA Culture Status
NCT01537783 (1) [back to overview]	Recurrence of Cutaneous Abscess
NCT01594827 (9) [back to overview]	Change in Forced Expiratory Volume (FEV1)% Predicted From Baseline to Day 58
NCT01594827 (9) [back to overview]	Development of Antibiotic Resistance
NCT01594827 (9) [back to overview]	Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture
NCT01594827 (9) [back to overview]	Percentage of Patients MRSA Free by Induced Sputum Respiratory Tract Culture
NCT01594827 (9) [back to overview]	Time to First Anti-MRSA Antibiotics (After Treatment Period)
NCT01594827 (9) [back to overview]	Time to First CF Exacerbation
NCT01594827 (9) [back to overview]	Change if FEV1% Predicted From Screening
NCT01594827 (9) [back to overview]	Change in Patient Reported Quality of Life (CFQ-R)(Respiratory)
NCT01594827 (9) [back to overview]	Total Number of Pulmonary Exacerbations
NCT01814371 (15) [back to overview]	Number of All Recovered S. Aureus Isolates With High-level Mupirocin Resistance
NCT01814371 (15) [back to overview]	Number of Participants With Incidence of SSTI at 9 Months After Decolonization
NCT01814371 (15) [back to overview]	Number of Participants With Incidence of SSTI at 6 Months After Decolonization
NCT01814371 (15) [back to overview]	Number of Participants With Incidence of SSTI at 3 Months After Decolonization
NCT01814371 (15) [back to overview]	Number of Participants With Incidence of SSTI at 12 Months After Decolonization
NCT01814371 (15) [back to overview]	Number of Participants With Incidence of SSTI at 1 Month After Decolonization
NCT01814371 (15) [back to overview]	Number of Participants Adhering to Decolonization Measures
NCT01814371 (15) [back to overview]	Number of Participants Who Report Development of Adverse Effects Occurring During Decolonization Period
NCT01814371 (15) [back to overview]	Number of Participants Reporting a Confirmed MRSA Infection Over the 12-month Longitudinal Study Period.
NCT01814371 (15) [back to overview]	Number of Participants Incurring Economic Burden of Performing Protocol
NCT01814371 (15) [back to overview]	Number of Participants Colonized With MRSA at 9 Months After Decolonization
NCT01814371 (15) [back to overview]	Number of Participants Colonized With MRSA at 6 Months After Decolonization
NCT01814371 (15) [back to overview]	Number of Participants Colonized With MRSA at 3 Months After Decolonization
NCT01814371 (15) [back to overview]	Number of Participants Colonized With MRSA at 12 Months After Decolonization
NCT01814371 (15) [back to overview]	Number of Participants Colonized With MRSA at 1 Month After Decolonization
NCT01827358 (11) [back to overview]	Time Until Decolonization: Count of Participants From Day 1 Until the First NUP Collection With no SA is Detected in the Nares, Umbilical, and Perianal Areas Using the According to Protocol Day 8 (ATP-8) Cohort.
NCT01827358 (11) [back to overview]	Protective Efficacy of Clinical S. Aureus (SA) Infection in the Treatment Compared to the Control Group During Days 1-22 or Until Discharge, Whichever Occurs First, Using the Intent to Treat Cohort.
NCT01827358 (11) [back to overview]	Persistent Decolonization Efficacy- Number of Participants in the Treatment and Control Groups Who Have no Detectable S. Aureus (SA) on Direct Nasal, Umbilical, and Perianal (NUP) Cultures on Days 8 and 22.
NCT01827358 (11) [back to overview]	Primary Decolonization Efficacy- Number of Participants in the Treatment and Control Groups Who Have no Detectable S. Aureus (SA) on Direct Nasal, Umbilical, and Perianal (NUP) Cultures Obtained on Day 8.
NCT01827358 (11) [back to overview]	Number of Participants With Moderate and Severe Unsolicited Adverse Events; During Days 1-7
NCT01827358 (11) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) During Days 1-7
NCT01827358 (11) [back to overview]	Number of Participants With Solicited Adverse Events (AEs) During Days 1-7
NCT01827358 (11) [back to overview]	Protective Efficacy of Clinical SA Infection in the Treatment Compared to the Control Group During Days 1-22 or Until Discharge, Whichever Occurs First, Using the According to Protocol (ATP) Cohort.
NCT01827358 (11) [back to overview]	Relative Risk of Occurrence of Non-SA Clinical Infection in the Treatment Compared to Control Group in the According to Protocol Cohort.
NCT01827358 (11) [back to overview]	Relative Risk of Occurrence of Non-SA Clinical Infection in the Treatment Compared to Control Group in the Intent To Treat Cohort
NCT01827358 (11) [back to overview]	Time Until Decolonization: Count of Participants From Day 1 Until the First NUP Collection With no S. Aureus (SA) Detected in the Nares, Umbilical, and Perianal Areas Using the Modified Intent to Treat Day 8 Cohort (mITT-8).
NCT02029872 (1) [back to overview]	Number of Participants With Recurrent Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization
NCT02218307 (2) [back to overview]	Quality of Life in Chronic Rhinosinusitis Patients
NCT02218307 (2) [back to overview]	Quality of Life in Chronic Rhinosinusitis Patients
NCT02223520 (1) [back to overview]	Number of Neonatal Infections With a S. Aureus Strain That is Concordant to Parental S. Aureus Strain
NCT02284555 (2) [back to overview]	Apparent Eradication of Nasal Carriage of SA
NCT02284555 (2) [back to overview]	The Number of Subjects With Adverse Events and Changes in Vital Signs, ECG and Routine Haematology, Clinical Chemistry and Urinalysis Tests Assessed Over the Five Day Treatment Period and Follow-up at 7 and 14 Days Relative to the First Dose.
NCT03673956 (3) [back to overview]	Subjects Who Developed Antibiotic Resistance Organisms
NCT03673956 (3) [back to overview]	Change in Patient Symptoms as Measured by the Sino-Nasal Outcomes Test (SNOT-22) Survey
NCT03673956 (3) [back to overview]	Change in Patient Physical Exam as Measured by the Lund-Kennedy Endoscopic Exam Scores.
NCT03883828 (2) [back to overview]	Median Change in Quality of Life Scoring Rated by the Skindex-16 Dermatological Survey
NCT03883828 (2) [back to overview]	Number of Participants With Incidence of High Grade Radiation Dermatitis
NCT04155203 (1) [back to overview]	Proportion of Subjects in Each Treatment Group With Clinical Cure (Defined as a Skin Infection Rating Scale (SIRS) Score of 0 for All Signs and Symptoms)
NCT04218799 (2) [back to overview]	Change in the Abundance of Staphylococcus Aureus in the Throat After Decolonization
NCT04218799 (2) [back to overview]	Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization
NCT04222699 (2) [back to overview]	Change in the Abundance of Staphylococcus Aureus in the Throat After Decolonization
NCT04222699 (2) [back to overview]	Change in the Abundance of Staphylococcus Aureus in the Nose After Decolonization

Acquisition of New S. Aureus Strains

In the Mupirocin Ointment (Treatment) and Polyethylene Glycol (Placebo) Arms, S. aureus isolates (MSSA or MRSA) that caused infection prior to enrollment in the study were compared with S. aureus infecting isolates (MSSA or MRSA) that occurred during the study (re-infections). Infecting isolates that were found to be MRSA at enrollment and MRSA during the study were considered to be the same strain; this same strain definition was also applied to MSSA isolates. Infecting isolates that changed from MRSA at enrollment to MSSA during the study (or vice versa) were considered to be different strains. (NCT00108160)
Timeframe: 18 months

Intervention	participants (Number)
	Same strain baseline & Re-infection	MRSA Baseline & Re-Infection	MSSA Baseline & Re-Infection
Mupirocin Ointment (Treatment)	10	8	2
Polyethylene Glycol Ointment (Placebo)	10	10	0

Intervention	participants with S. aureus re-infection (Number)
	All enrolled participants [n=83,63)]	Completed visit 0 baseline [n=79,60]	Completed visit 1 (2 wks) ([n=72,54]	Completed visit 2 (3 mo) [n=54,46]	completed visit 3 (6 mo) [n=44,38]	completed visit 4 (9 mo) [n=38,37]	completed visit 5 (12 mo) [n=37,37]	completed visit 6 (15 mo) [n=36,33]	completed visit 7 (18 mo) [n=34,31]
Mupirocin Ointment (Treatment)	10	0	1	2	2	3	0	1	1
Polyethylene Glycol Ointment (Placebo)	11	0	0	3	4	1	0	2	1

Intervention	participants (Number)
	All Re-Infections	Re-infections Different Anatomic Site
Mupirocin Ointment [Treatment]	10	7
Polyethylene Glycol Ointment [Placebo]	11	6

Intervention	Change in EASI Score (Mean)
	Exposed Sites: Head and Neck	Bath-Submerged Sites: Limbs and Trunk
Placebo	-0.57	-0.88
Treatment	-1.06	-4.94

Intervention	Participants (Number)
Hygiene Education	24
Hygiene Education + Mupirocin	35
Education + Mupirocin + Chlorhexidine	35
Education + Mupirocin + Bleach Baths	34

Intervention	Participants (Number)
1: Hygiene Education	31
2: Hygiene Education + Mupirocin	32
Education + Mupirocin + Chlorhexidine	31
4: Education + Mupirocin + Bleach Baths	36

Intervention	Participants (Number)
	1 Month Follow-up	4 Month Follow-up	6 Month Follow-up
1: Hygiene Education	17	26	28
2: Hygiene Education + Mupirocin	14	20	27
4: Education + Mupirocin + Bleach Baths	12	18	21
Education + Mupirocin + Chlorhexidine	7	19	23

Intervention	Participants (Count of Participants)
	Clinical cure	Clinical failure
Bactroban® TID	166	38
TD1414 BID	158	45
TD1414 TID	177	28

Intervention	Participants (Count of Participants)
	End of treatment (Day 8)72434489		End of treatment (Day 8)72434490	End of treatment (Day 8)72434488	Follow-up (Day 15)72434488	Follow-up (Day 15)72434490	Follow-up (Day 15)72434489	End of Treatment and follow-up72434488	End of Treatment and follow-up72434489	End of Treatment and follow-up72434490
	Bacteriological cure	Bacteriological failure
TD1414 BID	66
TD1414 TID	80
Bactroban® TID	94
TD1414 BID	44
TD1414 TID	41
Bactroban® TID	24
TD1414 BID	74
TD1414 TID	85
Bactroban® TID	102
TD1414 BID	36
TD1414 TID	36
Bactroban® TID	16
TD1414 BID	57
TD1414 TID	66
Bactroban® TID	86
TD1414 BID	53
TD1414 TID	55
Bactroban® TID	32

Intervention	Participants (Count of Participants)
Mupirocin/Hexachlorophene Group	12
Placebo Group	14
No MRSA Colonization	0

Intervention	Participants (Count of Participants)
	Nares	Throat	Perirectal	Groin	Axilla
Mupirocin/Hexachlorophene Group	17	NA	NA	NA	NA
No MRSA Colonization	0	0	0	0	0
Placebo Group	18	NA	NA	NA	NA

Intervention	Odds Ratio (Number)
	As randomized, unadjusted	As randomized, adjusted
Arm 1: Usual Care-Active Surveillance	0.74	0.73
Arm 2: Targeted Decolonization	0.94	0.93
Arm 3: Universal Decolonization	0.56	0.55

Intervention	Hazard Ratio (Number)
	High-level bacteriuria (all patients)	High-level bacteriuria (women)	High-level bacteriuria (men)	High-level candiduria (all patients)	High-level candiduria (women)	High-level candiduria (men)	Any bacteriuria (all patients)	Any bacteriuria (women)	Any bacteriuria (men)
Arm 1: Usual Care-Active Surveillance	1.02	0.97	1.09	1.14	1.09	1.21	.95	.91	1.01
Arm 2: Targeted Decolonization	0.88	0.83	1.01	.99	1.00	1.01	.92	.86	1.04
Arm 3: Universal Decolonization	0.87	0.93	.78	.83	.94	.63	.86	.95	.74

Intervention	Dollars per 1000 ICU-admissions (Number)
	Cost of MRSA screening tests	Cost of contact precautions	Cost of decolonization	ICU costs (not including intervention costs)
Arm 1: Usual Care-Active Surveillance	9,120	69,010	0	19,320,000
Arm 2: Targeted Decolonization	9,120	68,830	4,679	19,250,000
Arm 3: Universal Decolonization	0	24,890	36,500	19,170,000

Intervention	Odds Ratio (Number)
	Clinical MRSA: LLMR	Clinical MRSA: HLMR	ICU-attributable MRSA: LLMR	ICU-attributable MRSA: HLMR
Arm 1: Usual Care-Active Surveillance	1.0	0.8	1.7	1.5
Arm 2: Targeted Decolonization	1.4	0.9	0.4	0.7
Arm 3: Universal Decolonization	0.5	0.7	0.7	1.4

Intervention	Hazard ratio (Number)
Arm 1: Usual Care-Active Surveillance	0.99
Arm 2: Targeted Decolonization	0.78
Arm 3: Universal Decolonization	0.56

Intervention	% predicted FEV1 (Median)
Inhaled Vancomycin and Oral Antibiotics	-2.5
Inhaled Placebo (Sterile Water) and Oral Antibiotics	1.0

Intervention	Days (Mean)
Inhaled Vancomycin and Oral Antibiotics	NA
Inhaled Placebo (Sterile Water) and Oral Antibiotics	68.4

Intervention	FEV1% predicted (Mean)
	Day 29	Day 58	Day 118
Inhaled Placebo (Sterile Water) and Oral Antibiotics	1.1	1.3	-0.3
Inhaled Vancomycin and Oral Antibiotics	0.0	-3.0	-2.1

Intervention	Participants (Count of Participants)
	Day 1-8 at risk	Day 1-8 with decolonization	Day 1-8 censored	Day 9-15 at risk	Day 9-15 with decolonization	Day 9-15 censored	Day 16-22 at risk	Day 16-22 with decolonization	Day 16-22 censored
Mupirocin (Treatment)	64	57	1	6	3	0	3	0	3
No Mupirocin (Control)	63	2	14	47	0	4	43	0	43

Intervention	Participants (Count of Participants)
	Day 1-8 at risk	Day 1-8 with clinical SA infection	Day 1-8 censored	Day 9-15 at risk	Day 9-15 with clinical SA infection	Day 9-15 censored	Day 16-22 at risk	Day 16-22 with clinical SA infection	Day 16-22 censored
Mupirocin (Treatment)	78	0	5	73	1	11	61	0	61
No Mupirocin (Control)	73	2	6	65	1	12	52	1	51

mupirocin

Description

Cross-References

Synonyms (117)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (6)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (63)

Molecular Functions (39)

Ceullar Components (28)

Bioassays (270)

Research

Studies (1,308)

Market Indicators

Research Demand Index: 104.81

Study Types

Clinical Trials (68)

Trial Overview

Trial Outcomes

Acquisition of New S. Aureus Strains

Re-infection With S. Aureus

S. Aureus Re-infections (New or Recurrent)

Change in Eczema Area and Severity Index (EASI)Scores According to Location

Number of Participants Eradicated of S. Aureus Carriage - 1 Month After Intervention

Number of Participants Eradicated of S. Aureus Carriage - 4 Months After Intervention

Number of Participants With Recurrent Staphylococcus Aureus Skin or Soft Tissue Infection

Participants With Clinical Cure According to Investigator's Assessment.

Participants With Bacteriological Cure According to Bacteriological Samples

Participants With Clinical and Bacteriological Cure According to Investigator's Assessment and Bacteriological Samples

The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA Colonization

To Determine the Prevalence and Incidence of MRSA Colonization of the Nares, Throat, Perirectal, Axilla, and Groin Areas Among HIV Infected Patients and to Study Changes in the Colonization Rates Over Time.

Number of Index Patients Eradicated of S. Aureus Carriage - 3 Month After Performing Decolonization Measures

Number of Index Patients Eradicated of S. Aureus Carriage - 1 Month After Performing Decolonization Measures

Number of Index Patients Eradicated of S. Aureus Carriage - 12 Month After Performing Decolonization Measures

Number of Index Patients Eradicated of S. Aureus Carriage - 6 Month After Performing Decolonization Measures

Recurrence of CA-MRSA Skin or Soft Tissue Infection - 1 Month After Enrollment.

Recurrence of CA-MRSA Skin or Soft Tissue Infection - 12 Month After Enrollment.

Recurrence of CA-MRSA Skin or Soft Tissue Infection - 3 Month After Enrollment.

Recurrence of CA-MRSA Skin or Soft Tissue Infection - 6 Month After Enrollment.

Blood Culture Contamination Rates

Intervention Impact on Bacteriuria and Candiduria

Intervention Impact on Healthcare Costs

Intervention Impact on Mupirocin Susceptibility of MRSA Isolates

ICU-attributable All-pathogen Bloodstream Infection

Intervention Impact on Chlorhexidine Susceptibility of MRSA Isolates

Main Outcome: Patients With Nosocomial MRSA Clinical Cultures

MRSA Bloodstream Infection

Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.

Surgical Site Infections Occurring Within 12 Months of Surgical Procedure

Pulmonary Exacerbations

Antibiotic Use (Days of Use Per Subject)

Antibiotic Use (Proportion of Subjects)

MRSA Culture Status

Recurrence of Cutaneous Abscess

Change in Forced Expiratory Volume (FEV1)% Predicted From Baseline to Day 58

Development of Antibiotic Resistance

Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture

Percentage of Patients MRSA Free by Induced Sputum Respiratory Tract Culture

Time to First Anti-MRSA Antibiotics (After Treatment Period)

Time to First CF Exacerbation

Change if FEV1% Predicted From Screening

Change in Patient Reported Quality of Life (CFQ-R)(Respiratory)

Total Number of Pulmonary Exacerbations

Number of All Recovered S. Aureus Isolates With High-level Mupirocin Resistance

Number of Participants With Incidence of SSTI at 9 Months After Decolonization

Number of Participants With Incidence of SSTI at 6 Months After Decolonization

Intervention	participants (Number)
	Cardiac failure	Heart disease congenital	Incarcerated inguinal hernia	Necrotising colitis	Candida infection	Pneumonia	Rhinovirus infection
Mupirocin (Treatment)	1	1	1	0	1	1	0
No Mupirocin (Control)	0	0	0	1	0	0	1

Intervention	Participants (Count of Participants)
	Staphylococcal bacteremia	Heart disease congenital	Incarcerated inguinal hernia	Infantile apnoea
Mupirocin (Treatment)	1	1	1	1
No Mupirocin (Control)	0	0	0	0

Intervention	participants (Number)
	Fever	Rash	Swelling of nasal mucosa	Epistaxis	Diarrhea	Apnea/ bradycardia/ desaturation events	Apnea within 3-5 minutes of mupirocin application	Pain within 3-5 minutes of mupirocin application	Any Symptom
Mupirocin (Treatment)	2	17	1	0	9	43	8	15	60
No Mupirocin (Control)	1	4	0	0	7	45	NA	NA	65

Intervention	Participants (Count of Participants)
	Day 1-8 at risk	Day 1-8 with clinical non-SA infection	Day 1-8 censored	Day 9-15 at Risk	Day 9-15 with clinical non-SA infection	Day 9-15 censored	Day 16-22 at risk	Day 16-22 with non-SA infection	Day 16-22 censored	Day 23-29 at risk	Day 23-29 with clinical non-SA infection	Day 23-29 censored	Day 30-36 at risk	Day 30-36 with clinical non-SA infection	Day 30-36 censored	Day 37-43 at risk	Day 37-43 with clinical non-SA infection	Day 37-43 censored	Day 44-50 at risk	Day 44-50 with clinical non-SA infection	Day 44-50 censored	Day 51-57 at risk	Day 51-57 with clinical non-SA infection	Day 51-57 censored	Day 58-64 at risk	Day 58-64 with clinical non-SA infection	Day 58-64 censored	Day 65-71 at risk	Day 65-71 with clinical non-SA infection	Day 65-71 censored	Day 72-78 at risk	Day 72-78 with clinical non-SA infection	Day 72-78 censored	Day 79-85 at risk	Day 79-85 with clinical non-SA infection	Day 79-85 censored
Mupirocin (Treatment)	67	3	3	61	0	9	52	0	11	41	0	4	37	1	4	32	1	4	27	0	8	19	1	0	18	0	4	14	0	5	9	0	3	6	0	6
No Mupirocin (Control)	66	1	4	61	0	11	50	0	4	46	3	13	30	0	6	24	0	7	17	0	6	11	0	2	9	0	4	5	0	1	4	0	0	4	0	4

Intervention	neonatal S. aureus infections (Number)
Mupirocin and Chlorhexidine	13
Placebo Ointment and Placebo Cloths	29

Intervention	Participants (Count of Participants)
Mupirocin Antibiotic Nasal Saline Rinse	0
Tobramycin Topical Antibiotic Nasal Saline Rinse	0
Levofloxacin Topical Antibiotic Nasal Saline Rinse	1
Vancomycin Topical Antibiotic Nasal Saline Rinse	0

Intervention	units on a scale (Mean)
Mupirocin Antibiotic Nasal Saline Rinse	-5.3
Tobramycin Topical Antibiotic Nasal Saline Rinse	-3
Levofloxacin Topical Antibiotic Nasal Saline Rinse	-2.4
Vancomycin Topical Antibiotic Nasal Saline Rinse	0